<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Transl Hepatol</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Transl Hepatol</journal-id><journal-id journal-id-type="publisher-id">JCTH</journal-id><journal-title-group><journal-title>Journal of Clinical and Translational Hepatology</journal-title></journal-title-group><issn pub-type="ppub">2225-0719</issn><issn pub-type="epub">2310-8819</issn><publisher><publisher-name>XIA &amp; HE Publishing Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26357625</article-id><article-id pub-id-type="pmc">4521243</article-id><article-id pub-id-type="publisher-id">JCTH419126</article-id><article-id pub-id-type="doi">10.14218/JCTH.2014.00013</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Hepatocellular Carcinoma and Liver Transplantation: State of the Art</article-title><alt-title alt-title-type="running-head">Hepatocellular carcinoma and liver transplantation: State of the art</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mancuso</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Perricone</surname><given-names>Giovanni</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Epatologia e Gastroenterologia, Ospedale Niguarda Ca' Granda, Milano, Italy</aff><aff id="aff2"><label>2</label>Medicina Interna 1, Azienda di Rilievo Nazionale ad Alta Specializzazione Civico - Di Cristina – Benfratelli, Palermo, Italy</aff><author-notes><corresp id="cor1"><label>*</label><bold>Correspondence to:</bold> Andrea Mancuso, Medicina Interna 1, A.R.N.A.S. Civico, Piazzale Liotti 4, Palermo 90100, Italy. Tel: +39-329-899-7893, Fax: +39-091-609-0252. E-mail: <email xlink:href="mancandrea@libero.it">mancandrea@libero.it</email></corresp><fn fn-type="conflict"><p><bold>Conflict of interest:</bold> None</p></fn><fn fn-type="con"><p><bold>Author contributions:</bold> Writing the review (AM, GP).</p></fn></author-notes><pub-date pub-type="epub"><day>15</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2014</year></pub-date><volume>2</volume><issue>3</issue><fpage>176</fpage><lpage>181</lpage><history><date date-type="received"><day>23</day><month>4</month><year>2014</year></date><date date-type="rev-recd"><day>30</day><month>6</month><year>2014</year></date><date date-type="accepted"><day>01</day><month>7</month><year>2014</year></date></history><permissions><copyright-statement>© 2014 The Second Affiliated Hospital of Chongqing Medical University. Published by XIA &amp; HE Publishing Ltd. All rights reserved.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><offsets xml_i="3628" xml_f="3782" txt_i="11" txt_f="165">Hepatocellular carcinoma (HCC) is an aggressive tumor that often occurs in chronic liver disease and cirrhosis. The incidence of HCC is growing worldwide.</offsets></p><p><offsets xml_i="3789" xml_f="4343" txt_i="166" txt_f="720">With respect to any other available treatment for liver cancer, liver transplantation (LT) has the highest potential to cure. LT allows for removal at once of both the tumor (“seed”) and the damaged-hepatic tissue (“soil”) where cancerogenesis and chronic liver disorders have progressed together. The Milan criteria (MC) have been applied worldwide to select patients with HCC for LT, yielding a 4-year survival rate of 75%. These criteria represent the benchmark for patient selection and are the basis for comparison with any other suggested criteria.</offsets></p><p><offsets xml_i="4350" xml_f="5211" txt_i="721" txt_f="1582">However, MC are often considered to be too restrictive, and recent data show that between 25% and 50% of patients with HCC are currently transplanted beyond conventional indications. Consequently, any unrestricted expansion of selection criteria will increase the need for donor organs, lengthen waiting periods, increase drop-out rates, and impair outcomes on intention-to-treat analysis. Management of HCC recurrence after LT is challenging. There are a few reports available regarding the safety and efficacy of sorafenib for HCC recurrence after LT, but the data are heterogeneous. A multi-center prospective randomized controlled trial comparing placebo with sorafenib is advised. Alternatively, a meta-analysis of patient survival with sorafenib for HCC recurrence after LT could be helpful to characterize the therapeutic benefit and safety of sorafenib.</offsets></p><p><offsets xml_i="5218" xml_f="5391" txt_i="1583" txt_f="1756">Here, we review the use of LT for HCC, with particular emphasis on the selection criteria for transplantation in patients with HCC and management of HCC recurrence after LT.</offsets></p></abstract><kwd-group><kwd>Hepatocellular carcinoma</kwd><kwd>Liver transplantation</kwd><kwd>Selection criteria</kwd><kwd>Milan criteria</kwd><kwd>Recurrence</kwd><kwd>Sorafenib</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><title><offsets xml_i="5657" xml_f="5669" txt_i="1764" txt_f="1776">Introduction</offsets></title><p><offsets xml_i="5680" xml_f="6016" txt_i="1777" txt_f="2113">Liver cancer is the second most common cause of death from cancer worldwide, estimated to be responsible for nearly 746,000 deaths in 2012 (9.1% of the total). The prognosis for liver cancer is very poor, with an overall ratio of mortality to incidence of 0.95, and the geographical patterns in incidence and mortality are similar (see </offsets><xref ref-type="table" rid="t01"><offsets xml_i="6049" xml_f="6056" txt_i="2113" txt_f="2120">Table 1</offsets></xref><offsets xml_i="6063" xml_f="6065" txt_i="2120" txt_f="2122">).</offsets><xref rid="b1" ref-type="bibr"><offsets xml_i="6096" xml_f="6097" txt_i="2122" txt_f="2123">1</offsets></xref><offsets xml_i="6104" xml_f="6105" txt_i="2123" txt_f="2124">
</offsets></p><table-wrap id="t01" position="float"><label><offsets xml_i="6154" xml_f="6161" txt_i="2125" txt_f="2132">Table 1</offsets></label><caption><title><offsets xml_i="6185" xml_f="6270" txt_i="2132" txt_f="2217">Liver cancer. Estimated incidence, mortality, and 5-year prevalence worldwide in 2012</offsets></title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="left" valign="middle" colspan="1"><offsets xml_i="6393" xml_f="6422" txt_i="2218" txt_f="2247">Estimated numbers (thousands)</offsets></th><th colspan="3" align="center" rowspan="1"><offsets xml_i="6470" xml_f="6473" txt_i="2247" txt_f="2250">Men</offsets></th><th colspan="3" align="center" rowspan="1"><offsets xml_i="6521" xml_f="6526" txt_i="2250" txt_f="2255">Women</offsets></th><th colspan="3" align="center" rowspan="1"><offsets xml_i="6574" xml_f="6584" txt_i="2255" txt_f="2265">Both sexes</offsets></th></tr><tr><th colspan="9" align="center" rowspan="1"><hr></hr></th></tr><tr><th align="center" rowspan="1" colspan="1"><offsets xml_i="6707" xml_f="6712" txt_i="2265" txt_f="2270">Cases</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="6760" xml_f="6766" txt_i="2270" txt_f="2276">Deaths</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="6814" xml_f="6823" txt_i="2276" txt_f="2285">5-yr prev</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="6871" xml_f="6876" txt_i="2285" txt_f="2290">Cases</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="6924" xml_f="6930" txt_i="2290" txt_f="2296">Deaths</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="6978" xml_f="6987" txt_i="2296" txt_f="2305">5-yr prev</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="7035" xml_f="7040" txt_i="2305" txt_f="2310">Cases</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="7088" xml_f="7094" txt_i="2310" txt_f="2316">Deaths</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="7142" xml_f="7151" txt_i="2316" txt_f="2325">5-yr prev</offsets></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="7221" xml_f="7226" txt_i="2325" txt_f="2330">World</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="7274" xml_f="7277" txt_i="2331" txt_f="2334">554</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="7325" xml_f="7328" txt_i="2335" txt_f="2338">521</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="7376" xml_f="7379" txt_i="2339" txt_f="2342">453</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="7427" xml_f="7430" txt_i="2343" txt_f="2346">228</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="7478" xml_f="7481" txt_i="2347" txt_f="2350">224</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="7529" xml_f="7532" txt_i="2351" txt_f="2354">180</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="7580" xml_f="7583" txt_i="2355" txt_f="2358">782</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="7631" xml_f="7634" txt_i="2359" txt_f="2362">746</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="7682" xml_f="7685" txt_i="2363" txt_f="2366">633</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="7740" xml_f="7762" txt_i="2367" txt_f="2389">More developed regions</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="7810" xml_f="7812" txt_i="2390" txt_f="2392">92</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="7860" xml_f="7862" txt_i="2393" txt_f="2395">80</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="7910" xml_f="7913" txt_i="2396" txt_f="2399">112</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="7961" xml_f="7963" txt_i="2400" txt_f="2402">42</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="8011" xml_f="8013" txt_i="2403" txt_f="2405">43</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="8061" xml_f="8063" txt_i="2406" txt_f="2408">51</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="8111" xml_f="8114" txt_i="2409" txt_f="2412">134</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="8162" xml_f="8165" txt_i="2413" txt_f="2416">123</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="8213" xml_f="8216" txt_i="2417" txt_f="2420">164</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="8271" xml_f="8293" txt_i="2421" txt_f="2443">Less developed regions</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="8341" xml_f="8344" txt_i="2444" txt_f="2447">462</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="8392" xml_f="8395" txt_i="2448" txt_f="2451">441</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="8443" xml_f="8446" txt_i="2452" txt_f="2455">341</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="8494" xml_f="8497" txt_i="2456" txt_f="2459">186</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="8545" xml_f="8548" txt_i="2460" txt_f="2463">182</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="8596" xml_f="8599" txt_i="2464" txt_f="2467">129</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="8647" xml_f="8650" txt_i="2468" txt_f="2471">648</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="8698" xml_f="8701" txt_i="2472" txt_f="2475">622</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="8749" xml_f="8752" txt_i="2476" txt_f="2479">469</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="8807" xml_f="8810" txt_i="2480" txt_f="2483">USA</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="8858" xml_f="8860" txt_i="2484" txt_f="2486">23</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="8908" xml_f="8910" txt_i="2487" txt_f="2489">17</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="8958" xml_f="8960" txt_i="2490" txt_f="2492">21</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9008" xml_f="9009" txt_i="2493" txt_f="2494">8</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9057" xml_f="9058" txt_i="2495" txt_f="2496">7</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9106" xml_f="9107" txt_i="2497" txt_f="2498">7</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9155" xml_f="9157" txt_i="2499" txt_f="2501">30</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9205" xml_f="9207" txt_i="2502" txt_f="2504">24</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9255" xml_f="9257" txt_i="2505" txt_f="2507">27</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="9312" xml_f="9317" txt_i="2508" txt_f="2513">China</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9365" xml_f="9368" txt_i="2514" txt_f="2517">293</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9416" xml_f="9419" txt_i="2518" txt_f="2521">282</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9467" xml_f="9470" txt_i="2522" txt_f="2525">220</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9518" xml_f="9521" txt_i="2526" txt_f="2529">101</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9569" xml_f="9572" txt_i="2530" txt_f="2533">101</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9620" xml_f="9622" txt_i="2534" txt_f="2536">71</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9670" xml_f="9673" txt_i="2537" txt_f="2540">395</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9721" xml_f="9724" txt_i="2541" txt_f="2544">383</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9772" xml_f="9775" txt_i="2545" txt_f="2548">291</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="9830" xml_f="9835" txt_i="2549" txt_f="2554">India</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9883" xml_f="9885" txt_i="2555" txt_f="2557">17</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9933" xml_f="9935" txt_i="2558" txt_f="2560">17</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="9983" xml_f="9984" txt_i="2561" txt_f="2562">8</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10032" xml_f="10034" txt_i="2563" txt_f="2565">10</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10082" xml_f="10084" txt_i="2566" txt_f="2568">10</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10132" xml_f="10133" txt_i="2569" txt_f="2570">5</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10181" xml_f="10183" txt_i="2571" txt_f="2573">27</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10231" xml_f="10233" txt_i="2574" txt_f="2576">27</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10281" xml_f="10283" txt_i="2577" txt_f="2579">13</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="10338" xml_f="10352" txt_i="2580" txt_f="2594">European Union</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10400" xml_f="10402" txt_i="2595" txt_f="2597">36</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10450" xml_f="10452" txt_i="2598" txt_f="2600">32</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10500" xml_f="10502" txt_i="2601" txt_f="2603">33</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10550" xml_f="10552" txt_i="2604" txt_f="2606">16</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10600" xml_f="10602" txt_i="2607" txt_f="2609">17</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10650" xml_f="10652" txt_i="2610" txt_f="2612">14</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10700" xml_f="10702" txt_i="2613" txt_f="2615">52</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10750" xml_f="10752" txt_i="2616" txt_f="2618">48</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="10800" xml_f="10802" txt_i="2619" txt_f="2621">47</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="10852" xml_f="10874" txt_i="2622" txt_f="2644">Source: Globoscan 2012</offsets></p></fn></table-wrap-foot></table-wrap><p><offsets xml_i="10917" xml_f="11121" txt_i="2645" txt_f="2849">HCC represents more than 90% of primary liver cancers and is a major global health problem. The incidence of HCC increases progressively with advancing age in all populations, reaching a peak at 70 years.</offsets><xref rid="b2" ref-type="bibr"><offsets xml_i="11152" xml_f="11153" txt_i="2849" txt_f="2850">2</offsets></xref><offsets xml_i="11160" xml_f="11246" txt_i="2850" txt_f="2936"> HCC has a strong male preponderance, with a male to female ratio estimated to be 2.4.</offsets><xref rid="b1" ref-type="bibr"><offsets xml_i="11277" xml_f="11278" txt_i="2936" txt_f="2937">1</offsets></xref><offsets xml_i="11285" xml_f="11354" txt_i="2937" txt_f="3006"> The pattern of HCC occurrence has a clear geographical distribution.</offsets><xref rid="b1" ref-type="bibr"><offsets xml_i="11385" xml_f="11386" txt_i="3006" txt_f="3007">1</offsets></xref><offsets xml_i="11393" xml_f="11394" txt_i="3007" txt_f="3008">,</offsets><xref rid="b3" ref-type="bibr"><offsets xml_i="11425" xml_f="11426" txt_i="3008" txt_f="3009">3</offsets></xref><offsets xml_i="11433" xml_f="11534" txt_i="3009" txt_f="3110"> In 2012, 83% of the estimated 782,000 new cancer cases worldwide occurred in less developed regions.</offsets><xref rid="b1" ref-type="bibr"><offsets xml_i="11565" xml_f="11566" txt_i="3110" txt_f="3111">1</offsets></xref><offsets xml_i="11573" xml_f="11616" txt_i="3111" txt_f="3154"> The incidence of HCC is growing worldwide.</offsets></p><p><offsets xml_i="11623" xml_f="12056" txt_i="3155" txt_f="3588">A variety of important risk factors for the development of HCC have been identified. These include chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, alcohol intake, hereditary hemochromatosis, aflatoxin exposure, and cirrhosis of almost any cause. However, HCC can also occur in patients without known risk factors. Approximately 90% of HCC are associated with a known underlying risk factor (see </offsets><xref ref-type="table" rid="t02"><offsets xml_i="12089" xml_f="12096" txt_i="3588" txt_f="3595">Table 2</offsets></xref><offsets xml_i="12103" xml_f="12571" txt_i="3595" txt_f="4063">). Cirrhosis may be caused by chronic viral hepatitis, alcohol, inherited metabolic diseases such as hemochromatosis or alpha-1-antitrypsin deficiency or Wilson's disease, non-alcoholic fatty liver disease, autoimmune hepatitis, and Budd-Chiari syndrome. All etiologic forms of cirrhosis may be complicated by tumor formation, but the risk is higher in patients with hepatitis infection. Overall, one-third of cirrhotic patients will develop HCC during their lifetime.</offsets><xref rid="b3" ref-type="bibr"><offsets xml_i="12602" xml_f="12603" txt_i="4063" txt_f="4064">3</offsets></xref><offsets xml_i="12610" xml_f="12611" txt_i="4064" txt_f="4065">–</offsets><xref rid="b7" ref-type="bibr"><offsets xml_i="12642" xml_f="12643" txt_i="4065" txt_f="4066">7</offsets></xref><offsets xml_i="12650" xml_f="12703" txt_i="4066" txt_f="4119"> Rarely, HCC can develop in the absence of cirrhosis.</offsets></p><table-wrap id="t02" position="float"><label><offsets xml_i="12752" xml_f="12759" txt_i="4120" txt_f="4127">Table 2</offsets></label><caption><title><offsets xml_i="12783" xml_f="12847" txt_i="4127" txt_f="4191">Geographical distribution of main risk factors for HCC worldwide</offsets></title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="12954" xml_f="12969" txt_i="4192" txt_f="4207">Geographic area</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="13017" xml_f="13025" txt_i="4207" txt_f="4215">AAIR M/F</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="13073" xml_f="13093" txt_i="4215" txt_f="4235">Risk factors HCV (%)</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="13141" xml_f="13148" txt_i="4235" txt_f="4242">HBV (%)</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="13196" xml_f="13207" txt_i="4242" txt_f="4253">Alcohol (%)</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="13255" xml_f="13265" txt_i="4253" txt_f="4263">Others (%)</offsets></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="13335" xml_f="13341" txt_i="4263" txt_f="4269">Europe</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="13389" xml_f="13396" txt_i="4270" txt_f="4277">6.7/2.3</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="13444" xml_f="13449" txt_i="4278" txt_f="4283">60–70</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="13497" xml_f="13502" txt_i="4284" txt_f="4289">10–15</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="13550" xml_f="13552" txt_i="4290" txt_f="4292">20</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="13600" xml_f="13602" txt_i="4293" txt_f="4295">10</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="13657" xml_f="13666" txt_i="4296" txt_f="4305"> Southern</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="13714" xml_f="13722" txt_i="4306" txt_f="4314">10.5/3.3</offsets></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="13961" xml_f="13970" txt_i="4319" txt_f="4328"> Northern</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14018" xml_f="14025" txt_i="4329" txt_f="4336">4.1/1.8</offsets></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="14264" xml_f="14277" txt_i="4341" txt_f="4354">North America</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14325" xml_f="14332" txt_i="4355" txt_f="4362">6.8/2.3</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14380" xml_f="14385" txt_i="4363" txt_f="4368">50–60</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14433" xml_f="14435" txt_i="4369" txt_f="4371">20</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14483" xml_f="14485" txt_i="4372" txt_f="4374">20</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14533" xml_f="14541" txt_i="4375" txt_f="4383">10(NASH)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="14596" xml_f="14611" txt_i="4384" txt_f="4399">Asia and Africa</offsets></td><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14705" xml_f="14707" txt_i="4401" txt_f="4403">20</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14755" xml_f="14757" txt_i="4404" txt_f="4406">70</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14805" xml_f="14807" txt_i="4407" txt_f="4409">10</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14855" xml_f="14868" txt_i="4410" txt_f="4423">10(Aflatoxin)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="14923" xml_f="14927" txt_i="4424" txt_f="4428">Asia</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14975" xml_f="14983" txt_i="4429" txt_f="4437">21.6/8.2</offsets></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="15222" xml_f="15228" txt_i="4442" txt_f="4448"> China</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15276" xml_f="15282" txt_i="4449" txt_f="4455">23/9.6</offsets></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="15521" xml_f="15527" txt_i="4460" txt_f="4466"> Japan</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15575" xml_f="15583" txt_i="4467" txt_f="4475">20.5/7.8</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15631" xml_f="15633" txt_i="4476" txt_f="4478">70</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15681" xml_f="15686" txt_i="4479" txt_f="4484">10–20</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15734" xml_f="15736" txt_i="4485" txt_f="4487">10</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15784" xml_f="15786" txt_i="4488" txt_f="4490">10</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="15841" xml_f="15847" txt_i="4491" txt_f="4497">Africa</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15895" xml_f="15902" txt_i="4498" txt_f="4505">1.6/5.3</offsets></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="16141" xml_f="16146" txt_i="4510" txt_f="4515">World</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16194" xml_f="16198" txt_i="4516" txt_f="4520">16/6</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16246" xml_f="16248" txt_i="4521" txt_f="4523">31</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16296" xml_f="16298" txt_i="4524" txt_f="4526">54</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16346" xml_f="16348" txt_i="4527" txt_f="4529">15</offsets></td><td align="left" rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="16444" xml_f="16526" txt_i="4531" txt_f="4613">AAIR, Age-adjusted incidence rate; HBV, Hepatitis B virus; HCV, Hepatitis C virus.</offsets></p></fn><fn><p><offsets xml_i="16542" xml_f="16543" txt_i="4614" txt_f="4615">
</offsets><italic><offsets xml_i="16551" xml_f="16596" txt_i="4615" txt_f="4660">Updated from Llovet et. al. according to IARC</offsets></italic><xref rid="b1" ref-type="bibr"><italic><offsets xml_i="16644" xml_f="16645" txt_i="4660" txt_f="4661">1</offsets></italic></xref></p></fn></table-wrap-foot></table-wrap><p><offsets xml_i="16704" xml_f="17178" txt_i="4662" txt_f="5136">Overall, the incidence of HCC is increasing not only in the general population of patients with cirrhosis, but also in some subgroups of patients, like those with human immunodeficiency virus (HIV) infection or thalassemia. In fact, significant improvement in outcomes due to iron chelating drugs in thalassaemic patients and to highly active anti-retroviral therapy (HAART) in HIV patients has recently revealed HCC as a main complication of the underlying hepatic disease.</offsets><xref rid="b8" ref-type="bibr"><offsets xml_i="17209" xml_f="17210" txt_i="5136" txt_f="5137">8</offsets></xref><offsets xml_i="17217" xml_f="17218" txt_i="5137" txt_f="5138">–</offsets><xref rid="b13" ref-type="bibr"><offsets xml_i="17250" xml_f="17252" txt_i="5138" txt_f="5140">13</offsets></xref><offsets xml_i="17259" xml_f="17260" txt_i="5140" txt_f="5141">
</offsets></p><p><offsets xml_i="17267" xml_f="17330" txt_i="5142" txt_f="5205">Liver transplantation (LT) is an established treatment for HCC.</offsets><xref rid="b14" ref-type="bibr"><offsets xml_i="17362" xml_f="17364" txt_i="5205" txt_f="5207">14</offsets></xref><offsets xml_i="17371" xml_f="17372" txt_i="5207" txt_f="5208">,</offsets><xref rid="b15" ref-type="bibr"><offsets xml_i="17404" xml_f="17406" txt_i="5208" txt_f="5210">15</offsets></xref><offsets xml_i="17413" xml_f="17644" txt_i="5210" txt_f="5441"> If donor graft supply was unlimited, every cirrhotic patient with HCC would be offered LT as the optimal treatment for their disease. Relative to any other available treatment for liver cancer, LT has the highest potential to cure</offsets><xref rid="b4" ref-type="bibr"><offsets xml_i="17675" xml_f="17676" txt_i="5441" txt_f="5442">4</offsets></xref><offsets xml_i="17683" xml_f="17684" txt_i="5442" txt_f="5443">,</offsets><xref rid="b6" ref-type="bibr"><offsets xml_i="17715" xml_f="17716" txt_i="5443" txt_f="5444">6</offsets></xref><offsets xml_i="17723" xml_f="17890" txt_i="5444" txt_f="5611"> because of its ability to remove at once both the seeded-HCC and the damaged-hepatic tissue where cancerogenesis and chronic liver disorders have together progressed.</offsets><xref rid="b16" ref-type="bibr"><offsets xml_i="17922" xml_f="17924" txt_i="5611" txt_f="5613">16</offsets></xref><offsets xml_i="17931" xml_f="17932" txt_i="5613" txt_f="5614">
</offsets></p><p><offsets xml_i="17939" xml_f="18236" txt_i="5615" txt_f="5912">The criteria for determining whether a HCC patient is eligible, upfront, for LT are very heterogeneous and relatively ill-defined. Another controversy is how to manage HCC recurrence after LT because there is little evidence available regarding improvement of survival with any treatment after LT.</offsets></p><p><offsets xml_i="18243" xml_f="18459" txt_i="5913" txt_f="6129">Here, we present a state-of-the-art review on LT for HCC. In particular, this review concentrates on two topics, respectively, selection criteria for LT in patients with HCC and management of HCC recurrence after LT.</offsets></p></sec><sec id="s2"><title><offsets xml_i="18489" xml_f="18613" txt_i="6131" txt_f="6255">Selection criteria for liver transplantation in patients with hepatocellular carcinoma: Milan criteria or expanded criteria?</offsets></title><p><offsets xml_i="18624" xml_f="18738" txt_i="6256" txt_f="6370">The number of LTs for HCC has increased worldwide; and currently in Europe, about 27% of all LT patients have HCC.</offsets><xref rid="b18" ref-type="bibr"><offsets xml_i="18770" xml_f="18772" txt_i="6370" txt_f="6372">18</offsets></xref><offsets xml_i="18779" xml_f="19018" txt_i="6372" txt_f="6611"> More specifically, in some Mediterranean areas of France, Italy, and Spain, LT for HCC represents more than 40% of transplants. Over the last decade in Western countries, HCC has had the highest growth increment of all indications for LT.</offsets><xref rid="b17" ref-type="bibr"><offsets xml_i="19050" xml_f="19052" txt_i="6611" txt_f="6613">17</offsets></xref><offsets xml_i="19059" xml_f="19060" txt_i="6613" txt_f="6614">,</offsets><xref rid="b18" ref-type="bibr"><offsets xml_i="19092" xml_f="19094" txt_i="6614" txt_f="6616">18</offsets></xref><offsets xml_i="19101" xml_f="19264" txt_i="6616" txt_f="6779"> This trend is even more pronounced in Eastern countries, where HCC, in some instances, has equalized or even overtaken cirrhosis as the leading indication for LT.</offsets><xref rid="b19" ref-type="bibr"><offsets xml_i="19296" xml_f="19298" txt_i="6779" txt_f="6781">19</offsets></xref><offsets xml_i="19305" xml_f="19306" txt_i="6781" txt_f="6782">
</offsets></p><p><offsets xml_i="19313" xml_f="19546" txt_i="6783" txt_f="7013">The broad selection criteria applied two decades ago led to poor results in terms of recurrence (32–54% at 5 years) and survival (5-year survival &lt;40%), but allowed for the identification of the best candidates for this procedure.</offsets><xref rid="b6" ref-type="bibr"><offsets xml_i="19577" xml_f="19578" txt_i="7013" txt_f="7014">6</offsets></xref><offsets xml_i="19585" xml_f="19586" txt_i="7014" txt_f="7015">,</offsets><xref rid="b20" ref-type="bibr"><offsets xml_i="19618" xml_f="19620" txt_i="7015" txt_f="7017">20</offsets></xref><offsets xml_i="19627" xml_f="19628" txt_i="7017" txt_f="7018">,</offsets><xref rid="b21" ref-type="bibr"><offsets xml_i="19660" xml_f="19662" txt_i="7018" txt_f="7020">21</offsets></xref><offsets xml_i="19669" xml_f="20087" txt_i="7020" txt_f="7438"> Since the initial results of LT for HCC were negative, likely because LT was initially reserved for advanced HCC not suitable for resection, the reliability of the procedure was questioned. In 1996, the publication of a pivotal prospective study on 48 patients transplanted for HCC under predefined criteria (single HCC ≤5 cm or 3 HCC ≤3 cm each), the so called “Milan criteria” (MC), showed a 4 year survival of 75%.</offsets><xref rid="b22" ref-type="bibr"><offsets xml_i="20119" xml_f="20121" txt_i="7438" txt_f="7440">22</offsets></xref><offsets xml_i="20128" xml_f="20259" txt_i="7440" txt_f="7571"> Successively, some pioneering groups selecting “optimal candidates” reported 70% 5-year survival with a recurrence rate below 15%.</offsets><xref rid="b23" ref-type="bibr"><offsets xml_i="20291" xml_f="20293" txt_i="7571" txt_f="7573">23</offsets></xref><offsets xml_i="20300" xml_f="20301" txt_i="7573" txt_f="7574">–</offsets><xref rid="b26" ref-type="bibr"><offsets xml_i="20333" xml_f="20335" txt_i="7574" txt_f="7576">26</offsets></xref><offsets xml_i="20342" xml_f="20474" txt_i="7576" txt_f="7708"> Due to these data, LT is now considered to be the first-line treatment for patients with single HCC ≤5 cm or 3 HCC ≤3 cm each (see </offsets><xref ref-type="table" rid="t03"><offsets xml_i="20507" xml_f="20514" txt_i="7708" txt_f="7715">Table 3</offsets></xref><offsets xml_i="20521" xml_f="20523" txt_i="7715" txt_f="7717">).</offsets><xref rid="b4" ref-type="bibr"><offsets xml_i="20554" xml_f="20555" txt_i="7717" txt_f="7718">4</offsets></xref><offsets xml_i="20562" xml_f="20563" txt_i="7718" txt_f="7719">–</offsets><xref rid="b6" ref-type="bibr"><offsets xml_i="20594" xml_f="20595" txt_i="7719" txt_f="7720">6</offsets></xref><offsets xml_i="20602" xml_f="20708" txt_i="7720" txt_f="7826"> All publication to date use the strict guidelines set by the MC when considering LT for treatment of HCC.</offsets><xref rid="b4" ref-type="bibr"><offsets xml_i="20739" xml_f="20740" txt_i="7826" txt_f="7827">4</offsets></xref><offsets xml_i="20747" xml_f="20748" txt_i="7827" txt_f="7828">–</offsets><xref rid="b6" ref-type="bibr"><offsets xml_i="20779" xml_f="20780" txt_i="7828" txt_f="7829">6</offsets></xref><offsets xml_i="20787" xml_f="21108" txt_i="7829" txt_f="8150"> A meta-analysis has confirmed the strong association of MC with a survival advantage (HR 1.7) and with a low risk of selecting an aggressive biologic behavior with respect to patients exceeding them. In fact, G3 tumors and microvascular invasion are less frequent when MC are met, with a HR of 4.8 and 2.5, respectively.</offsets><xref rid="b27" ref-type="bibr"><offsets xml_i="21140" xml_f="21142" txt_i="8150" txt_f="8152">27</offsets></xref><offsets xml_i="21149" xml_f="21150" txt_i="8152" txt_f="8153">
</offsets></p><table-wrap id="t03" position="float"><label><offsets xml_i="21199" xml_f="21206" txt_i="8154" txt_f="8161">Table 3</offsets></label><caption><title><offsets xml_i="21230" xml_f="21596" txt_i="8161" txt_f="8527">Recommendations on liver transplantation for hepatocellular carcinoma based on the level of evidence and the strength of the data (classification of evidence adapted from National Cancer Institute) and the strength of recommendations following previously reported systems (GRADE systems), according to EASL-EORTC clinical practice guidelines on the management of HCC</offsets><xref rid="b6" ref-type="bibr"><offsets xml_i="21627" xml_f="21628" txt_i="8527" txt_f="8528">6</offsets></xref><offsets xml_i="21635" xml_f="21636" txt_i="8528" txt_f="8529">
</offsets></title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="21791" xml_f="21809" txt_i="8530" txt_f="8548">Levels of evidence</offsets><xref ref-type="table-fn" rid="nt103"><offsets xml_i="21847" xml_f="21848" txt_i="8548" txt_f="8549">*</offsets></xref><offsets xml_i="21855" xml_f="21856" txt_i="8549" txt_f="8550">
</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="21904" xml_f="21927" txt_i="8550" txt_f="8573">Grade of recommendation</offsets><xref ref-type="table-fn" rid="nt104"><offsets xml_i="21965" xml_f="21966" txt_i="8573" txt_f="8574">°</offsets></xref><offsets xml_i="21973" xml_f="21974" txt_i="8574" txt_f="8575">
</offsets></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="22044" xml_f="22056" txt_i="8575" txt_f="8587">LT Milano IN</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="22104" xml_f="22106" txt_i="8588" txt_f="8590">2A</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="22154" xml_f="22156" txt_i="8591" txt_f="8593">1A</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="22211" xml_f="22215" txt_i="8594" txt_f="8598">LDLT</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="22263" xml_f="22265" txt_i="8599" txt_f="8601">2A</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="22313" xml_f="22315" txt_i="8602" txt_f="8604">2B</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="22370" xml_f="22381" txt_i="8605" txt_f="8616">LT extended</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="22429" xml_f="22431" txt_i="8617" txt_f="8619">2B</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="22479" xml_f="22481" txt_i="8620" txt_f="8622">2B</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="22536" xml_f="22548" txt_i="8623" txt_f="8635">Down-staging</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="22596" xml_f="22598" txt_i="8636" txt_f="8638">2D</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="22646" xml_f="22648" txt_i="8639" txt_f="8641">2C</offsets></td></tr></tbody></table><table-wrap-foot><fn id="nt103"><label><offsets xml_i="22713" xml_f="22714" txt_i="8642" txt_f="8643">*</offsets></label><p><offsets xml_i="22725" xml_f="22763" txt_i="8643" txt_f="8681">Adapted from National Cancer Institute</offsets></p></fn><fn id="nt104"><label><offsets xml_i="22794" xml_f="22795" txt_i="8682" txt_f="8683">°</offsets></label><p><offsets xml_i="22806" xml_f="22818" txt_i="8683" txt_f="8695">GRADE system</offsets></p></fn><fn><p><offsets xml_i="22834" xml_f="22902" txt_i="8696" txt_f="8764">LT, Liver transplantation; LDLT, Living donor liver transplantation.</offsets></p></fn></table-wrap-foot></table-wrap><p><offsets xml_i="22945" xml_f="23125" txt_i="8765" txt_f="8945">According to European (ELTR) and American (OPTN) registries, the overall 5-year survival of patients transplanted within the MC (65–78%) is similar to non-HCC indications (65–87%).</offsets><xref rid="b27" ref-type="bibr"><offsets xml_i="23157" xml_f="23159" txt_i="8945" txt_f="8947">27</offsets></xref><offsets xml_i="23166" xml_f="23167" txt_i="8947" txt_f="8948">–</offsets><xref rid="b29" ref-type="bibr"><offsets xml_i="23199" xml_f="23201" txt_i="8948" txt_f="8950">29</offsets></xref><offsets xml_i="23208" xml_f="23298" txt_i="8950" txt_f="9040"> As a consequence of their success, the MC have been integrated in the BCLC staging system</offsets><xref rid="b30" ref-type="bibr"><offsets xml_i="23330" xml_f="23332" txt_i="9040" txt_f="9042">30</offsets></xref><offsets xml_i="23339" xml_f="23340" txt_i="9042" txt_f="9043">,</offsets><xref rid="b31" ref-type="bibr"><offsets xml_i="23372" xml_f="23374" txt_i="9043" txt_f="9045">31</offsets></xref><offsets xml_i="23381" xml_f="23487" txt_i="9045" txt_f="9151"> and in the United Network for Organ Sharing (UNOS) pre-transplant staging for organ allocation in the US,</offsets><xref rid="b32" ref-type="bibr"><offsets xml_i="23519" xml_f="23521" txt_i="9151" txt_f="9153">32</offsets></xref><offsets xml_i="23528" xml_f="23664" txt_i="9153" txt_f="9289"> and remain the benchmark for any other prognostic criteria proposed for expanding the indication for LT in cirrhotic patients with HCC.</offsets><xref rid="b33" ref-type="bibr"><offsets xml_i="23696" xml_f="23698" txt_i="9289" txt_f="9291">33</offsets></xref><offsets xml_i="23705" xml_f="23706" txt_i="9291" txt_f="9292">
</offsets></p><p><offsets xml_i="23713" xml_f="24150" txt_i="9293" txt_f="9730">The need to obtain the optimal benefit from the limited number of organs that are available has prompted the maintenance of strict selection criteria so as to list only those patients with early HCC who have the highest likelihood of survival after transplant. However, this means that some patients with slightly more advanced HCC in whom transplant would offer an acceptable, but not excellent outcome, are excluded from the procedure.</offsets><xref rid="b34" ref-type="bibr"><offsets xml_i="24182" xml_f="24184" txt_i="9730" txt_f="9732">34</offsets></xref><offsets xml_i="24191" xml_f="24192" txt_i="9732" txt_f="9733">–</offsets><xref rid="b36" ref-type="bibr"><offsets xml_i="24224" xml_f="24226" txt_i="9733" txt_f="9735">36</offsets></xref><offsets xml_i="24233" xml_f="24234" txt_i="9735" txt_f="9736">
</offsets></p><p><offsets xml_i="24241" xml_f="24813" txt_i="9737" txt_f="10309">Nevertheless, MC are often considered to be too restrictive and a plethora of “expanded criteria” have been suggested. In summary, in order to establish a new policy allowing for expansion of criteria for transplantation, it is essential to develop robust data for the specific category of patients included in the proposed expansion. Novel criteria might have a major impact on all transplant programs and the data needed to support any change should be impeccable. In addition, the impact of the expansion on non-HCC patients waiting for LT should be taken into account.</offsets><xref rid="b3" ref-type="bibr"><offsets xml_i="24844" xml_f="24845" txt_i="10309" txt_f="10310">3</offsets></xref><offsets xml_i="24852" xml_f="24853" txt_i="10310" txt_f="10311">
</offsets></p><p><offsets xml_i="24860" xml_f="25322" txt_i="10312" txt_f="10774">None of these expanded criteria have been prospectively and independently validated. The partial exceptions are the University of San Francisco (UCSF) criteria (single tumor ≤6.5 cm or multiple HCC ≤3 nodules ≤4.5 cm, with the total tumor diameter ≤8 cm). Notably, there is a significant overlap between patients meeting the Milan and the UCSF criteria, resulting in a modest expansion of the exact number of HCC patients eligible for LT (estimated to be 5–10%).</offsets><xref rid="b37" ref-type="bibr"><offsets xml_i="25354" xml_f="25356" txt_i="10774" txt_f="10776">37</offsets></xref><offsets xml_i="25363" xml_f="25551" txt_i="10776" txt_f="10964"> In fact, UCSF criteria on explant identified retrospectively a cohort of patients whose survival was not significantly different from those of patients transplanted for HCC inside the MC.</offsets><xref rid="b38" ref-type="bibr"><offsets xml_i="25583" xml_f="25585" txt_i="10964" txt_f="10966">38</offsets></xref><offsets xml_i="25592" xml_f="25862" txt_i="10966" txt_f="11236"> The same results have been demonstrated by other retrospective experiences from other centers using UCSF criteria. Moreover, a recent prospective study showed a 5 year survival not significantly different in patients transplanted for HCC inside Milan and UCSF criteria.</offsets><xref rid="b39" ref-type="bibr"><offsets xml_i="25894" xml_f="25896" txt_i="11236" txt_f="11238">39</offsets></xref><offsets xml_i="25903" xml_f="25904" txt_i="11238" txt_f="11239">
</offsets></p><p><offsets xml_i="25911" xml_f="26143" txt_i="11240" txt_f="11472">Today, expansion to UCSF criteria has already been challenged from the pathological point of view by the up-to-seven criteria (i.e. those HCC having the number 7 as the sum of the size of the largest tumor and the number of tumors).</offsets><xref rid="b36" ref-type="bibr"><offsets xml_i="26175" xml_f="26177" txt_i="11472" txt_f="11474">36</offsets></xref><offsets xml_i="26184" xml_f="26557" txt_i="11474" txt_f="11847"> In a multicenter retrospective study on over 1,700 explants, the authors demonstrated that HCC inside the “up-to-seven” criteria at explant and without microvascular invasion had a 5 year survival not significantly different from those inside the MC, while survival was significantly worst in cases of HCC inside the “up-to-seven” criteria and with microvascular invasion.</offsets><xref rid="b36" ref-type="bibr"><offsets xml_i="26589" xml_f="26591" txt_i="11847" txt_f="11849">36</offsets></xref><offsets xml_i="26598" xml_f="26682" txt_i="11849" txt_f="11933"> This pathology-based proposal has been recently validated in an independent series,</offsets><xref rid="b40" ref-type="bibr"><offsets xml_i="26714" xml_f="26716" txt_i="11933" txt_f="11935">40</offsets></xref><offsets xml_i="26723" xml_f="26830" txt_i="11935" txt_f="12042"> but the findings must be further validated with prospective studies and is not suitable clinical practice.</offsets></p><p><offsets xml_i="26837" xml_f="27394" txt_i="12043" txt_f="12600">The major concerns about the expansion proposals are the lack of specific data on overall survival and drop-out rate on the waiting list for the patients outside the current criteria but fulfilling the expanded criteria. Other recent studies challenging the Milan criteria have proposed different algorithms to optimize patient selection. Nonetheless, 5-year outcome prediction could vary from 70% to 40% depending on the presence of microvascular invasion. Thus, preoperative markers of vascular invasion would be required prior to adopting these criteria.</offsets><xref rid="b6" ref-type="bibr"><offsets xml_i="27425" xml_f="27426" txt_i="12600" txt_f="12601">6</offsets></xref><offsets xml_i="27433" xml_f="27434" txt_i="12601" txt_f="12602">
</offsets></p><p><offsets xml_i="27441" xml_f="27714" txt_i="12603" txt_f="12876">Presently, it is likely that a modest expansion of the number of potential candidates may be considered for validated criteria (such as the up-to-seven criteria that largely include the UCSF criteria), which demonstrate comparable survival for patients outside the MC (see </offsets><xref ref-type="table" rid="t03"><offsets xml_i="27747" xml_f="27754" txt_i="12876" txt_f="12883">Table 3</offsets></xref><offsets xml_i="27761" xml_f="27763" txt_i="12883" txt_f="12885">).</offsets><xref rid="b6" ref-type="bibr"><offsets xml_i="27794" xml_f="27795" txt_i="12885" txt_f="12886">6</offsets></xref><offsets xml_i="27802" xml_f="27803" txt_i="12886" txt_f="12887">,</offsets><xref rid="b16" ref-type="bibr"><offsets xml_i="27835" xml_f="27837" txt_i="12887" txt_f="12889">16</offsets></xref><offsets xml_i="27844" xml_f="28102" txt_i="12889" txt_f="13147"> As repeatedly noted in scientific and regulatory contexts, any unrestricted expansion of selection criteria will increase the need for donor organs, lengthen waiting periods, increase drop-out rates, and impair outcomes on intention-to-treat (ITT) analyses.</offsets></p><p><offsets xml_i="28109" xml_f="28246" txt_i="13148" txt_f="13285">In the present context, the term “down-staging” defines the reduction of the intra-hepatic HCC burden to meet acceptable criteria for LT,</offsets><xref rid="b41" ref-type="bibr"><offsets xml_i="28278" xml_f="28280" txt_i="13285" txt_f="13287">41</offsets></xref><offsets xml_i="28287" xml_f="28358" txt_i="13287" txt_f="13358"> “acceptable” criteria being driven by good expected survival after LT.</offsets><xref rid="b42" ref-type="bibr"><offsets xml_i="28390" xml_f="28392" txt_i="13358" txt_f="13360">42</offsets></xref><offsets xml_i="28399" xml_f="28529" txt_i="13360" txt_f="13490"> This equates to a 5-year survival comparable to that of HCC patients who meet transplant criteria without requiring down-staging.</offsets><xref rid="b33" ref-type="bibr"><offsets xml_i="28561" xml_f="28563" txt_i="13490" txt_f="13492">33</offsets></xref><offsets xml_i="28570" xml_f="28740" txt_i="13492" txt_f="13662"> Namely, the principle of down-staging is to select a more favorable tumor biology, as determined by response to treatment in the perspective of positive post-LT outcome.</offsets><xref rid="b42" ref-type="bibr"><offsets xml_i="28772" xml_f="28774" txt_i="13662" txt_f="13664">41</offsets></xref><offsets xml_i="28781" xml_f="29140" txt_i="13664" txt_f="14023"> From the seminal experience of the UCSF group, most of the published reports have used the MC as the endpoint for down-staging. In doing so, for a minimal observation period of 3 months (suggested to confirm a sustained response to treatment), a comparable or only slightly reduced survival than that achieved with HCC meeting MC before LT has been reported.</offsets><xref rid="b41" ref-type="bibr"><offsets xml_i="29172" xml_f="29174" txt_i="14023" txt_f="14025">41</offsets></xref><offsets xml_i="29181" xml_f="29182" txt_i="14025" txt_f="14026">
</offsets></p><p><offsets xml_i="29189" xml_f="29365" txt_i="14027" txt_f="14203">According to recommendations, either MC or a modest expansion can be targeted in elective LT for HCC, while for down-staging only conversions to conventional MC are acceptable.</offsets><xref rid="b33" ref-type="bibr"><offsets xml_i="29397" xml_f="29399" txt_i="14203" txt_f="14205">33</offsets></xref><offsets xml_i="29406" xml_f="29605" txt_i="14205" txt_f="14404"> Trans-arterial chemoembolization (TACE) is the single treatment modality most often applied to HCC down-staging, followed by radiofrequency ablation (RFA), radioembolization, and surgical resection.</offsets><xref rid="b43" ref-type="bibr"><offsets xml_i="29637" xml_f="29639" txt_i="14404" txt_f="14406">43</offsets></xref><offsets xml_i="29646" xml_f="29647" txt_i="14406" txt_f="14407">–</offsets><xref rid="b48" ref-type="bibr"><offsets xml_i="29679" xml_f="29681" txt_i="14407" txt_f="14409">48</offsets></xref><offsets xml_i="29688" xml_f="29839" txt_i="14409" txt_f="14560"> In the large majority of centers, the choice of treatment – either alone or in combination – is made within multidisciplinary transplant-tumor boards.</offsets><xref rid="b49" ref-type="bibr"><offsets xml_i="29871" xml_f="29873" txt_i="14560" txt_f="14562">49</offsets></xref><offsets xml_i="29880" xml_f="30192" txt_i="14562" txt_f="14874"> Although a treatment strategy based on the individual components of patients/tumors is largely justified, it raises concerns of selection bias when a comparison among treatment strategies is attempted. The same applies to the criteria of exclusion from down-staging procedures, which remain largely undescribed.</offsets><xref rid="b16" ref-type="bibr"><offsets xml_i="30224" xml_f="30226" txt_i="14874" txt_f="14876">16</offsets></xref><offsets xml_i="30233" xml_f="30234" txt_i="14876" txt_f="14877">
</offsets></p><p><offsets xml_i="30241" xml_f="30400" txt_i="14878" txt_f="15037">Considering the current data, down-staging of patients beyond MC cannot be adopted as a tool to refine patient selection and further research is required (see </offsets><xref ref-type="table" rid="t03"><offsets xml_i="30433" xml_f="30440" txt_i="15037" txt_f="15044">Table 3</offsets></xref><offsets xml_i="30447" xml_f="30449" txt_i="15044" txt_f="15046">).</offsets><xref rid="b6" ref-type="bibr"><offsets xml_i="30480" xml_f="30481" txt_i="15046" txt_f="15047">6</offsets></xref><offsets xml_i="30488" xml_f="31073" txt_i="15047" txt_f="15632"> This research should be based on the principle that 5-year survival outcomes of patients undergoing transplantation after successful down-staging should be similar to those of patients transplanted following MC. The EASL-EORTC panel considers, though, that a special policy should be adopted for patients already on the waiting list for LT with tumors progressing beyond MC and liver only disease. In this special circumstance, it is recommended to place the candidate on hold until down-staging by local ablation or chemoembolization is achieved and maintained for at least 3 months.</offsets><xref rid="b6" ref-type="bibr"><offsets xml_i="31104" xml_f="31105" txt_i="15632" txt_f="15633">6</offsets></xref><offsets xml_i="31112" xml_f="31113" txt_i="15633" txt_f="15634">
</offsets></p><p><offsets xml_i="31120" xml_f="31183" txt_i="15635" txt_f="15698">In summary, guidelines still indicate LT only to HCC inside MC.</offsets><xref rid="b4" ref-type="bibr"><offsets xml_i="31214" xml_f="31215" txt_i="15698" txt_f="15699">4</offsets></xref><offsets xml_i="31222" xml_f="31223" txt_i="15699" txt_f="15700">–</offsets><xref rid="b6" ref-type="bibr"><offsets xml_i="31254" xml_f="31255" txt_i="15700" txt_f="15701">6</offsets></xref><offsets xml_i="31262" xml_f="31543" txt_i="15701" txt_f="15982"> However, as published experiences show, many centers perform LT outside the MC, using criteria that are different from center to center. Recent data show that even in large areas, between 25% and 50% of patients with HCC are currently transplanted beyond conventional indications.</offsets><xref rid="b33" ref-type="bibr"><offsets xml_i="31575" xml_f="31577" txt_i="15982" txt_f="15984">33</offsets></xref><offsets xml_i="31584" xml_f="31585" txt_i="15984" txt_f="15985">,</offsets><xref rid="b36" ref-type="bibr"><offsets xml_i="31617" xml_f="31619" txt_i="15985" txt_f="15987">36</offsets></xref><offsets xml_i="31626" xml_f="31627" txt_i="15987" txt_f="15988">,</offsets><xref rid="b38" ref-type="bibr"><offsets xml_i="31659" xml_f="31661" txt_i="15988" txt_f="15990">38</offsets></xref><offsets xml_i="31668" xml_f="31669" txt_i="15990" txt_f="15991">,</offsets><xref rid="b39" ref-type="bibr"><offsets xml_i="31701" xml_f="31703" txt_i="15991" txt_f="15993">39</offsets></xref><offsets xml_i="31710" xml_f="31711" txt_i="15993" txt_f="15994">,</offsets><xref rid="b50" ref-type="bibr"><offsets xml_i="31743" xml_f="31745" txt_i="15994" txt_f="15996">50</offsets></xref><offsets xml_i="31752" xml_f="31753" txt_i="15996" txt_f="15997">–</offsets><xref rid="b54" ref-type="bibr"><offsets xml_i="31785" xml_f="31787" txt_i="15997" txt_f="15999">54</offsets></xref><offsets xml_i="31794" xml_f="32101" txt_i="15999" txt_f="16306"> As a results, any unrestricted expansion of selection criteria will increase the need for donor organs, resulting in lengthened waiting periods, increased drop-out rates, and impaired outcomes in ITT analyses. Extreme deviations from efficiency and equity endpoints should be avoided in criteria expansion.</offsets></p><p></p><p><offsets xml_i="32115" xml_f="32260" txt_i="16308" txt_f="16453">Living donor liver transplantation (LDLT), where the right hepatic lobe of a healthy donor is used, has emerged as an alternative to deceased LT.</offsets><xref rid="b55" ref-type="bibr"><offsets xml_i="32292" xml_f="32294" txt_i="16453" txt_f="16455">55</offsets></xref><offsets xml_i="32301" xml_f="32302" txt_i="16455" txt_f="16456">–</offsets><xref rid="b56" ref-type="bibr"><offsets xml_i="32334" xml_f="32336" txt_i="16456" txt_f="16458">56</offsets></xref><offsets xml_i="32343" xml_f="32498" txt_i="16458" txt_f="16613"> In 2000, there was great enthusiasm for LDLT, and it was estimated that it would represent a significant proportion of the patients transplanted with HCC.</offsets><xref rid="b57" ref-type="bibr"><offsets xml_i="32530" xml_f="32532" txt_i="16613" txt_f="16615">57</offsets></xref><offsets xml_i="32539" xml_f="32724" txt_i="16615" txt_f="16800"> Unfortunately, the associated risks of death (estimated in 0.3%) and life-threatening complications (2%) for the healthy donor have diminished the interest of the transplant community.</offsets><xref rid="b58" ref-type="bibr"><offsets xml_i="32756" xml_f="32758" txt_i="16800" txt_f="16802">58</offsets></xref><offsets xml_i="32765" xml_f="32766" txt_i="16802" txt_f="16803">,</offsets><xref rid="b59" ref-type="bibr"><offsets xml_i="32798" xml_f="32800" txt_i="16803" txt_f="16805">59</offsets></xref><offsets xml_i="32807" xml_f="32808" txt_i="16805" txt_f="16806">,</offsets><xref rid="b60" ref-type="bibr"><offsets xml_i="32840" xml_f="32842" txt_i="16806" txt_f="16808">60</offsets></xref><offsets xml_i="32849" xml_f="32978" txt_i="16808" txt_f="16937"> Due to the complexity of the procedure, LDLT must be restricted to centers of excellence in hepatic surgery and transplantation.</offsets></p><p><offsets xml_i="32985" xml_f="33186" txt_i="16938" txt_f="17139">Outcome results with LDLT compared with deceased LT have been controversial. Although some studies suggested that LDLT was associated with higher risk of recurrence, these data have not been confirmed.</offsets><xref rid="b61" ref-type="bibr"><offsets xml_i="33218" xml_f="33220" txt_i="17139" txt_f="17141">61</offsets></xref><offsets xml_i="33227" xml_f="33228" txt_i="17141" txt_f="17142">,</offsets><xref rid="b62" ref-type="bibr"><offsets xml_i="33260" xml_f="33262" txt_i="17142" txt_f="17144">62</offsets></xref><offsets xml_i="33269" xml_f="33390" txt_i="17144" txt_f="17265"> Cost–effectiveness studies suggested that LDLT can be offered to patients with HCC if the waiting list exceeds 7 months,</offsets><xref rid="b63" ref-type="bibr"><offsets xml_i="33422" xml_f="33424" txt_i="17265" txt_f="17267">63</offsets></xref><offsets xml_i="33431" xml_f="33476" txt_i="17267" txt_f="17312"> a policy adopted by the panel of EASL-EORTC.</offsets><xref rid="b6" ref-type="bibr"><offsets xml_i="33507" xml_f="33508" txt_i="17312" txt_f="17313">6</offsets></xref><offsets xml_i="33515" xml_f="33516" txt_i="17313" txt_f="17314">
</offsets></p></sec><sec id="s3"><title><offsets xml_i="33546" xml_f="33672" txt_i="17316" txt_f="17442">Hepatocellular carcinoma recurrence after liver transplantation: the need of treatment despite no evidence of survival benefit</offsets></title><p><offsets xml_i="33683" xml_f="33969" txt_i="17443" txt_f="17729">Management of HCC recurrence after LT is complex and challenging. Despite the metastatic nature of such a recurrence, treatments resemble those used for HCC in cirrhosis, although there is no evidence that such treatments could improve survival of patients with HCC recurrence after LT.</offsets></p><p><offsets xml_i="33976" xml_f="34266" txt_i="17730" txt_f="18020">Approachable localized HCC recurrence should undergo surgery, with indication resembling those of HCC in cirrhosis. Recurrences not suitable for surgery should be treated with RFTA or TACE. However, both surgery and other treatments are empirical, as no evidence of survival benefit exists.</offsets></p><p><offsets xml_i="34273" xml_f="34428" txt_i="18021" txt_f="18176">Sorafenib is the treatment of choice for advanced HCC, since survival in sorafenib patients with underlying liver cirrhosis is longer than placebo control.</offsets><xref rid="b64" ref-type="bibr"><offsets xml_i="34460" xml_f="34462" txt_i="18176" txt_f="18178">64</offsets></xref><offsets xml_i="34469" xml_f="34470" txt_i="18178" txt_f="18179">,</offsets><xref rid="b65" ref-type="bibr"><offsets xml_i="34502" xml_f="34504" txt_i="18179" txt_f="18181">65</offsets></xref><offsets xml_i="34511" xml_f="34967" txt_i="18181" txt_f="18637"> Theoretically, such a systemic therapy could be the best approach for HCC recurrence after LT. However, different observational studies of patients treated with sorafenib for HCC recurrence after LT have reported contradictory results regarding safety and efficacy. In fact, while some authors emphasize the effectiveness and safety of sorafenib, pushing for the general acceptance of the treatment for HCC recurrence after LT, others had safety concerns.</offsets><xref rid="b66" ref-type="bibr"><offsets xml_i="34999" xml_f="35001" txt_i="18637" txt_f="18639">66</offsets></xref><offsets xml_i="35008" xml_f="35009" txt_i="18639" txt_f="18640">–</offsets><xref rid="b84" ref-type="bibr"><offsets xml_i="35041" xml_f="35043" txt_i="18640" txt_f="18642">84</offsets></xref><offsets xml_i="35050" xml_f="35179" txt_i="18642" txt_f="18771"> In particular, one group reported grade 3–4 adverse events in 92% of 13 patients, resulting in sorafenib discontinuation in 77%.</offsets><xref rid="b72" ref-type="bibr"><offsets xml_i="35211" xml_f="35213" txt_i="18771" txt_f="18773">72</offsets></xref><offsets xml_i="35220" xml_f="35352" txt_i="18773" txt_f="18905"> Another study of 11 consecutive patients described a high rate of intolerance or side-effects, causing drug discontinuation in 36%.</offsets><xref rid="b70" ref-type="bibr"><offsets xml_i="35384" xml_f="35386" txt_i="18905" txt_f="18907">70</offsets></xref><offsets xml_i="35393" xml_f="35598" txt_i="18907" txt_f="19112"> Moreover, some patients in another study died because of massive gastrointestinal bleeding, possibly due to an interaction between everolimus and sorafenib that could facilitate gastrointestinal bleeding.</offsets><xref rid="b69" ref-type="bibr"><offsets xml_i="35630" xml_f="35632" txt_i="19112" txt_f="19114">69</offsets></xref><offsets xml_i="35639" xml_f="35640" txt_i="19114" txt_f="19115">,</offsets><xref rid="b75" ref-type="bibr"><offsets xml_i="35672" xml_f="35674" txt_i="19115" txt_f="19117">75</offsets></xref><offsets xml_i="35681" xml_f="35682" txt_i="19117" txt_f="19118">,</offsets><xref rid="b85" ref-type="bibr"><offsets xml_i="35714" xml_f="35716" txt_i="19118" txt_f="19120">85</offsets></xref><offsets xml_i="35723" xml_f="35821" txt_i="19120" txt_f="19218"> In fact, a concern for the concomitant use of sorafenib and HAARTs in HIV has also been reported.</offsets><xref rid="b86" ref-type="bibr"><offsets xml_i="35853" xml_f="35855" txt_i="19218" txt_f="19220">86</offsets></xref><offsets xml_i="35862" xml_f="35863" txt_i="19220" txt_f="19221">
</offsets></p><p><offsets xml_i="35870" xml_f="36361" txt_i="19222" txt_f="19713">Taken all together, the experiences on treatment with sorafenib for HCC recurrence after LT are too heterogeneous to draw a definite conclusion and further studies are needed. It is advisable that the effort of a multi-center prospective randomized controlled sorafenib versus placebo trial should be made to address this controversial topic. Alternatively, a meta-analysis of survival of patients treated with sorafenib for HCC recurrence after LT could help to identify possible solutions.</offsets></p></sec><sec sec-type="conclusions" id="s4"><title><offsets xml_i="36414" xml_f="36425" txt_i="19715" txt_f="19726">Conclusions</offsets></title><p><offsets xml_i="36436" xml_f="37718" txt_i="19727" txt_f="21009">LT has the highest potential cure rate for HCC relative to other options, but the proportion of individuals with HCC on the waiting list for transplant is growing. The MC are the benchmark for patient selection and the basis for comparison with any other suggested criteria. Expansion of criteria is not a widely recommended strategy, since there is a lack of relevant evidence. Any expansion should avoid the saturation of the listing system and poor long-term outcomes after LT. Any unrestricted expansion of selection criteria will increase the need for donor organs, resulting in lengthened waiting periods, increased drop-out rates, and impaired outcomes in ITT analyses. Extreme deviations from efficiency and equity endpoints should be avoided in criteria expansion. “Down-staging” is the reduction of the intra-hepatic HCC burden to meet acceptable criteria for LT. The principle of the strategy is to select individuals whose tumors have a more favorable biology, as determined by treatment response in the perspective of positive post-LT outcome. However, treatment may not necessarily change the outcome of LT. Overall, down-staging is weakly recommended as a LT selection tool, unless it is applied in prospective studies with survival and disease-progression endpoints.</offsets></p></sec></body><back><ref-list><title>References</title><ref id="b1"><label>1</label><element-citation publication-type="book"><collab>IARC</collab><year>2012</year><comment>&lt;<ext-link ext-link-type="uri" xlink:href="http://www-dep.iarc.fr/">http://www-dep.iarc.fr/</ext-link>&gt;;</comment></element-citation></ref><ref id="b2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Serag</surname><given-names>HB</given-names></name><name><surname>Mason</surname><given-names>AC</given-names></name></person-group><article-title>Rising incidence of hepatocellular carcinoma in the United States</article-title><source>N Engl J Med</source><year>1999</year><volume>340</volume><fpage>745</fpage><lpage>750</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1056/NEJM199903113401001">10.1056/NEJM199903113401001</ext-link></comment><pub-id pub-id-type="pmid">10072408</pub-id></element-citation></ref><ref id="b3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Pisani</surname><given-names>P</given-names></name></person-group><article-title>Global cancer statistics, 2002</article-title><source>CA Cancer J Clin</source><year>2005</year><volume>55</volume><fpage>74</fpage><lpage>108</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.3322/canjclin.55.2.74">10.3322/canjclin.55.2.74</ext-link></comment><pub-id pub-id-type="pmid">15761078</pub-id></element-citation></ref><ref id="b4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruix</surname><given-names>J</given-names></name><name><surname>Sherman</surname><given-names>M</given-names></name><collab>American Association for the Study of Liver Diseases</collab></person-group><article-title>Management of Hepatocellular Carcinoma: An Update</article-title><source>Hepatology</source><year>2011</year><volume>53</volume><fpage>1020</fpage><lpage>1222</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1002/hep.24199">10.1002/hep.24199</ext-link></comment><pub-id pub-id-type="pmid">21374666</pub-id></element-citation></ref><ref id="b5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Izumi</surname><given-names>N</given-names></name><name><surname>Kokudo</surname><given-names>N</given-names></name><name><surname>Matsui</surname><given-names>O</given-names></name><name><surname>Sakamoto</surname><given-names>M</given-names></name><name><surname>Nakashima</surname><given-names>O</given-names></name><etal></etal></person-group><article-title>Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version</article-title><source>Dig Dis</source><year>2011</year><volume>29</volume><fpage>339</fpage><lpage>364</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1159/000327577">10.1159/000327577</ext-link></comment><pub-id pub-id-type="pmid">21829027</pub-id></element-citation></ref><ref id="b6"><label>6</label><element-citation publication-type="journal"><collab>European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer</collab><article-title>EASL-EORTC Clinical Practice Guidelines: Management of Hepatocellular Carcinoma</article-title><source>J Hepatol</source><year>2012</year><volume>56</volume><fpage>908</fpage><lpage>943</lpage><pub-id pub-id-type="pmid">22424438</pub-id></element-citation></ref><ref id="b7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sangiovanni</surname><given-names>A</given-names></name><name><surname>Prati</surname><given-names>GM</given-names></name><name><surname>Fasani</surname><given-names>P</given-names></name><name><surname>Ronchi</surname><given-names>G</given-names></name><name><surname>Romeo</surname><given-names>R</given-names></name><name><surname>Manini</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients</article-title><source>Hepatology</source><year>2006</year><volume>43</volume><fpage>1303</fpage><lpage>1310</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1002/hep.21176">10.1002/hep.21176</ext-link></comment><pub-id pub-id-type="pmid">16729298</pub-id></element-citation></ref><ref id="b8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ioannou</surname><given-names>GN</given-names></name><name><surname>Bryson</surname><given-names>CL</given-names></name><name><surname>Weiss</surname><given-names>NS</given-names></name><name><surname>Miller</surname><given-names>R</given-names></name><name><surname>Scott</surname><given-names>JD</given-names></name><name><surname>Boyko</surname><given-names>EJ</given-names></name></person-group><article-title>The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection</article-title><source>Hepatology</source><year>2013</year><volume>57</volume><fpage>249</fpage><lpage>257</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1002/hep.25800">10.1002/hep.25800</ext-link></comment><pub-id pub-id-type="pmid">22532055</pub-id></element-citation></ref><ref id="b9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahasrabuddhe</surname><given-names>VV</given-names></name><name><surname>Shiels</surname><given-names>MS</given-names></name><name><surname>McGlynn</surname><given-names>KA</given-names></name><name><surname>Engels</surname><given-names>EA</given-names></name></person-group><article-title>The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States</article-title><source>Cancer</source><year>2012</year><volume>118</volume><fpage>6226</fpage><lpage>6233</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1002/cncr.27694">10.1002/cncr.27694</ext-link></comment><pub-id pub-id-type="pmid">22736272</pub-id></element-citation></ref><ref id="b10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merchante</surname><given-names>N</given-names></name><name><surname>Merino</surname><given-names>E</given-names></name><name><surname>López-Aldeguer</surname><given-names>J</given-names></name><name><surname>Jover</surname><given-names>F</given-names></name><name><surname>Delgado-Fernández</surname><given-names>M</given-names></name><name><surname>Galindo</surname><given-names>MJ</given-names></name><etal></etal></person-group><article-title>Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain</article-title><source>Clin Infect Dis</source><year>2013</year><volume>56</volume><fpage>143</fpage><lpage>150</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1093/cid/cis777">10.1093/cid/cis777</ext-link></comment><pub-id pub-id-type="pmid">22955438</pub-id></element-citation></ref><ref id="b11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancuso</surname><given-names>A</given-names></name><name><surname>Rigano</surname><given-names>P</given-names></name><name><surname>Renda</surname><given-names>D</given-names></name><name><surname>Di Salvo</surname><given-names>V</given-names></name><name><surname>Pignatti</surname><given-names>CB</given-names></name><name><surname>Guddo</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Hepatocellular carcinoma on cirrhosis-free liver in a HCV-infected thalassemic</article-title><source>Am J Hematol</source><year>2005</year><volume>78</volume><fpage>158</fpage><lpage>159</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1002/ajh.20289">10.1002/ajh.20289</ext-link></comment><pub-id pub-id-type="pmid">15682406</pub-id></element-citation></ref><ref id="b12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancuso</surname><given-names>A</given-names></name><name><surname>Sciarrino</surname><given-names>E</given-names></name><name><surname>Renda</surname><given-names>MC</given-names></name><name><surname>Maggio</surname><given-names>A</given-names></name></person-group><article-title>A prospective study of hepatocellular carcinoma incidence in thalassemia</article-title><source>Hemoglobin</source><year>2006</year><volume>30</volume><fpage>119</fpage><lpage>124</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1080/03630260500455565">10.1080/03630260500455565</ext-link></comment><pub-id pub-id-type="pmid">16540424</pub-id></element-citation></ref><ref id="b13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancuso</surname><given-names>A</given-names></name></person-group><article-title>Hepatocellular carcinoma in thalassemia: A critical review</article-title><source>World J Hepatol</source><year>2010</year><volume>2</volume><fpage>171</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">21160991</pub-id></element-citation></ref><ref id="b14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forner</surname><given-names>A</given-names></name><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Bruix</surname><given-names>J</given-names></name></person-group><article-title>Hepatocellular carcinoma</article-title><source>Lancet</source><year>2012</year><volume>379</volume><fpage>1245</fpage><lpage>1255</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1016/S0140-6736(11)61347-0">10.1016/S0140-6736(11)61347-0</ext-link></comment><pub-id pub-id-type="pmid">22353262</pub-id></element-citation></ref><ref id="b15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Chun</surname><given-names>YS</given-names></name><name><surname>Poon</surname><given-names>RT</given-names></name><name><surname>Schwartz</surname><given-names>ME</given-names></name><name><surname>Yao</surname><given-names>FY</given-names></name><name><surname>Marsh</surname><given-names>JW</given-names></name><etal></etal></person-group><article-title>Liver transplantation for hepatocellular carcinoma</article-title><source>Ann Surg Oncol</source><year>2008</year><volume>15</volume><fpage>1001</fpage><lpage>1007</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1245/s10434-007-9559-5">10.1245/s10434-007-9559-5</ext-link></comment><pub-id pub-id-type="pmid">18236119</pub-id></element-citation></ref><ref id="b16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzaferro</surname><given-names>V</given-names></name></person-group><article-title>Selection criteria for HCC and downstaging procedures. In EASL postgraduate course. Transplantation &amp; the liver</article-title><source>EASL international liver congress</source><year>2013</year></element-citation></ref><ref id="b17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Karam</surname><given-names>V</given-names></name><name><surname>Delvart</surname><given-names>V</given-names></name><name><surname>O'Grady</surname><given-names>J</given-names></name><name><surname>Mirza</surname><given-names>D</given-names></name><name><surname>Klempnauer</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR)</article-title><source>J Hepatol</source><year>2012</year><volume>57</volume><fpage>675</fpage><lpage>688</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1016/j.jhep.2012.04.015">10.1016/j.jhep.2012.04.015</ext-link></comment><pub-id pub-id-type="pmid">22609307</pub-id></element-citation></ref><ref id="b18"><label>18</label><element-citation publication-type="book"><collab>OPTN/SRTR</collab><year>2011</year><comment>Annual Report;</comment></element-citation></ref><ref id="b19"><label>19</label><element-citation publication-type="book"><collab>China Liver Transplant Registry</collab><year>2012</year><comment><ext-link ext-link-type="uri" xlink:href="http://www.ilts.org/uploads/4_wang.pdf">http://www.ilts.org/uploads/4_wang.pdf</ext-link>.</comment></element-citation></ref><ref id="b20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwatsuki</surname><given-names>S</given-names></name><name><surname>Starzl</surname><given-names>TE</given-names></name><name><surname>Sheahan</surname><given-names>DG</given-names></name><name><surname>Yokoyama</surname><given-names>I</given-names></name><name><surname>Demetris</surname><given-names>AJ</given-names></name><name><surname>Todo</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Hepatic resection versus transplantation for hepatocellular carcinoma</article-title><source>Ann Surg</source><year>1991</year><volume>214</volume><fpage>221</fpage><lpage>228</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1097/00000658-199109000-00005">10.1097/00000658-199109000-00005</ext-link></comment><pub-id pub-id-type="pmid">1656903</pub-id></element-citation></ref><ref id="b21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwatsuki</surname><given-names>S</given-names></name><name><surname>Esquivel</surname><given-names>CO</given-names></name><name><surname>Gordon</surname><given-names>RD</given-names></name><name><surname>Shaw</surname><given-names>BW</given-names><suffix>Jr</suffix></name><name><surname>Starzl</surname><given-names>TE</given-names></name><name><surname>Shade</surname><given-names>RR</given-names></name><etal></etal></person-group><article-title>Liver transplantation for fulminant hepatic failure</article-title><source>Semin Liver Dis</source><year>1985</year><volume>5</volume><fpage>325</fpage><lpage>328</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1055/s-2008-1040628">10.1055/s-2008-1040628</ext-link></comment><pub-id pub-id-type="pmid">3909425</pub-id></element-citation></ref><ref id="b22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Regalia</surname><given-names>E</given-names></name><name><surname>Doci</surname><given-names>R</given-names></name><name><surname>Andreola</surname><given-names>S</given-names></name><name><surname>Pulvirenti</surname><given-names>A</given-names></name><name><surname>Bozzetti</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis</article-title><source>N Engl J Med</source><year>1996</year><volume>334</volume><fpage>693</fpage><lpage>699</lpage><pub-id pub-id-type="pmid">8594428</pub-id></element-citation></ref><ref id="b24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Fuster</surname><given-names>J</given-names></name><name><surname>Bruix</surname><given-names>J</given-names></name></person-group><article-title>Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation</article-title><source>Hepatology</source><year>1999</year><volume>30</volume><fpage>1434</fpage><lpage>1440</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1002/hep.510300629">10.1002/hep.510300629</ext-link></comment><pub-id pub-id-type="pmid">10573522</pub-id></element-citation></ref><ref id="b23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bismuth</surname><given-names>H</given-names></name><name><surname>Majno</surname><given-names>PE</given-names></name><name><surname>Adam</surname><given-names>R</given-names></name></person-group><article-title>Liver transplantation for hepatocellular carcinoma</article-title><source>Semin Liver Dis</source><year>1999</year><volume>19</volume><fpage>311</fpage><lpage>322</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1055/s-2007-1007120">10.1055/s-2007-1007120</ext-link></comment><pub-id pub-id-type="pmid">10518310</pub-id></element-citation></ref><ref id="b25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bismuth</surname><given-names>H</given-names></name><name><surname>Chiche</surname><given-names>L</given-names></name><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Castaing</surname><given-names>D</given-names></name><name><surname>Diamond</surname><given-names>T</given-names></name><name><surname>Dennison</surname><given-names>A</given-names></name></person-group><article-title>Liver resection versus transplantation for hepatocellular carcinoma in cirrhosis</article-title><source>Ann Surg</source><year>1993</year><volume>218</volume><fpage>145</fpage><lpage>151</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1097/00000658-199308000-00005">10.1097/00000658-199308000-00005</ext-link></comment><pub-id pub-id-type="pmid">8393649</pub-id></element-citation></ref><ref id="b26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonas</surname><given-names>S</given-names></name><name><surname>Bechstein</surname><given-names>WO</given-names></name><name><surname>Steinmüller</surname><given-names>T</given-names></name><name><surname>Herrmann</surname><given-names>M</given-names></name><name><surname>Radke</surname><given-names>C</given-names></name><name><surname>Berg</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis</article-title><source>Hepatology</source><year>2001</year><volume>33</volume><fpage>1080</fpage><lpage>1086</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1053/jhep.2001.23561">10.1053/jhep.2001.23561</ext-link></comment><pub-id pub-id-type="pmid">11343235</pub-id></element-citation></ref><ref id="b27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Bhoori</surname><given-names>S</given-names></name><name><surname>Sposito</surname><given-names>C</given-names></name><name><surname>Bongini</surname><given-names>M</given-names></name><name><surname>Langer</surname><given-names>M</given-names></name><name><surname>Miceli</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience</article-title><source>Liver Transpl</source><year>2011</year><volume>17</volume><issue>Suppl 2</issue><fpage>S44</fpage><lpage>57</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1002/lt.22365">10.1002/lt.22365</ext-link></comment><pub-id pub-id-type="pmid">21695773</pub-id></element-citation></ref><ref id="b28"><label>28</label><element-citation publication-type="book"><comment><ext-link ext-link-type="uri" xlink:href="http://www.eltr.org/">www.eltr.org/</ext-link>, accessed Nov 2011.</comment></element-citation></ref><ref id="b29"><label>29</label><element-citation publication-type="book"><comment><ext-link ext-link-type="uri" xlink:href="http://www.ustransplant.org/annual_reports/current/">http://www.ustransplant.org/annual_reports/current/</ext-link>, accessed Nov 2011.</comment></element-citation></ref><ref id="b30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Brú</surname><given-names>C</given-names></name><name><surname>Bruix</surname><given-names>J</given-names></name></person-group><article-title>Prognosis of hepatocellular carcinoma: the BCLC staging classification</article-title><source>Semin Liver Dis</source><year>1999</year><volume>19</volume><fpage>329</fpage><lpage>338</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1055/s-2007-1007122">10.1055/s-2007-1007122</ext-link></comment><pub-id pub-id-type="pmid">10518312</pub-id></element-citation></ref><ref id="b31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Di Bisceglie</surname><given-names>AM</given-names></name><name><surname>Bruix</surname><given-names>J</given-names></name><name><surname>Kramer</surname><given-names>BS</given-names></name><name><surname>Lencioni</surname><given-names>R</given-names></name><name><surname>Zhu</surname><given-names>AX</given-names></name><etal></etal></person-group><article-title>Design and endpoints of clinical trials in hepatocellular carcinoma</article-title><source>J Natl Cancer Inst</source><year>2008</year><volume>100</volume><fpage>698</fpage><lpage>711</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1093/jnci/djn134">10.1093/jnci/djn134</ext-link></comment><pub-id pub-id-type="pmid">18477802</pub-id></element-citation></ref><ref id="b32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>RB</given-names><suffix>Jr</suffix></name><name><surname>Wiesner</surname><given-names>RH</given-names></name><name><surname>Harper</surname><given-names>A</given-names></name><name><surname>McDiarmid</surname><given-names>SV</given-names></name><name><surname>Lake</surname><given-names>J</given-names></name><name><surname>Edwards</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>UNOS/OPTN Liver Disease Severity Score, UNOS/OPTN Liver and Intestine, and UNOS/OPTN Pediatric Transplantation Committees. The new liver allocation system: moving toward evidence-based transplantation policy</article-title><source>Liver Transpl</source><year>2002</year><volume>8</volume><fpage>851</fpage><lpage>858</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1053/jlts.2002.35927">10.1053/jlts.2002.35927</ext-link></comment><pub-id pub-id-type="pmid">12200791</pub-id></element-citation></ref><ref id="b34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clavien</surname><given-names>PA</given-names></name><name><surname>Lesurtel</surname><given-names>M</given-names></name><name><surname>Bossuyt</surname><given-names>PM</given-names></name><name><surname>Gores</surname><given-names>GJ</given-names></name><name><surname>Langer</surname><given-names>B</given-names></name><name><surname>Perrier</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report</article-title><source>Lancet Oncol</source><year>2012</year><volume>13</volume><fpage>e11</fpage><lpage>22</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1016/S1470-2045(11)70175-9">10.1016/S1470-2045(11)70175-9</ext-link></comment><pub-id pub-id-type="pmid">22047762</pub-id></element-citation></ref><ref id="b33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsh</surname><given-names>JW</given-names></name><name><surname>Dvorchik</surname><given-names>I</given-names></name><name><surname>Bonham</surname><given-names>CA</given-names></name><name><surname>Iwatsuki</surname><given-names>S</given-names></name></person-group><article-title>Is the pathologic TNM staging system for patients with hepatoma predictive of outcome?</article-title><source>Cancer</source><year>2000</year><volume>88</volume><fpage>538</fpage><lpage>543</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1002/(SICI)1097-0142(20000201)88:3&lt;538::AID-CNCR7&gt;3.0.CO;2-H">10.1002/(SICI)1097-0142(20000201)88:3&lt;538::AID-CNCR7&gt;3.0.CO;2-H</ext-link></comment><pub-id pub-id-type="pmid">10649244</pub-id></element-citation></ref><ref id="b35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsh</surname><given-names>JW</given-names></name><name><surname>Dvorchik</surname><given-names>I</given-names></name></person-group><article-title>Liver organ allocation for hepatocellular carcinoma: are we sure?</article-title><source>Liver Transpl</source><year>2003</year><volume>9</volume><fpage>693</fpage><lpage>696</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1053/jlts.2003.50086">10.1053/jlts.2003.50086</ext-link></comment><pub-id pub-id-type="pmid">12827554</pub-id></element-citation></ref><ref id="b36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Miceli</surname><given-names>R</given-names></name><name><surname>Bhoori</surname><given-names>S</given-names></name><name><surname>Schiavo</surname><given-names>M</given-names></name><name><surname>Mariani</surname><given-names>L</given-names></name><name><surname>Camerini</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis</article-title><source>Lancet Oncol</source><year>2009</year><volume>10</volume><fpage>35</fpage><lpage>43</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1016/S1470-2045(08)70284-5">10.1016/S1470-2045(08)70284-5</ext-link></comment><pub-id pub-id-type="pmid">19058754</pub-id></element-citation></ref><ref id="b37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>KR</given-names></name><name><surname>Young</surname><given-names>RS</given-names></name><name><surname>Burra</surname><given-names>P</given-names></name><name><surname>Zheng</surname><given-names>SS</given-names></name><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Moon</surname><given-names>DB</given-names></name><etal></etal></person-group><article-title>Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement</article-title><source>Liver Transpl</source><year>2011</year><volume>17</volume><issue>Suppl 2</issue><fpage>S81</fpage><lpage>89</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1002/lt.22380">10.1002/lt.22380</ext-link></comment><pub-id pub-id-type="pmid">21748847</pub-id></element-citation></ref><ref id="b38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>FY</given-names></name><name><surname>Ferrell</surname><given-names>L</given-names></name><name><surname>Bass</surname><given-names>NM</given-names></name><name><surname>Watson</surname><given-names>JJ</given-names></name><name><surname>Bacchetti</surname><given-names>P</given-names></name><name><surname>Venook</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival</article-title><source>Hepatology</source><year>2001</year><volume>33</volume><fpage>1394</fpage><lpage>1403</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1053/jhep.2001.24563">10.1053/jhep.2001.24563</ext-link></comment><pub-id pub-id-type="pmid">11391528</pub-id></element-citation></ref><ref id="b39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>FY</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Bass</surname><given-names>NM</given-names></name><name><surname>Kerlan</surname><given-names>R</given-names></name><name><surname>Ascher</surname><given-names>NL</given-names></name><name><surname>Roberts</surname><given-names>JP</given-names></name></person-group><article-title>Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging</article-title><source>Am J Transplant</source><year>2007</year><volume>7</volume><fpage>2587</fpage><lpage>2596</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1111/j.1600-6143.2007.01965.x.">10.1111/j.1600-6143.2007.01965.x.</ext-link></comment><pub-id pub-id-type="pmid">17868066</pub-id></element-citation></ref><ref id="b40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>A</given-names></name><name><surname>McCall</surname><given-names>J</given-names></name><name><surname>Gane</surname><given-names>E</given-names></name></person-group><article-title>Validation of the “Metroticket” predictor in a cohort of patients transplanted for predominantly HBV-related hepatocellular carcinoma</article-title><source>J Hepatol</source><year>2011</year><volume>55</volume><fpage>1063</fpage><lpage>1068</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1016/j.jhep.2011.01.052">10.1016/j.jhep.2011.01.052</ext-link></comment><pub-id pub-id-type="pmid">21354447</pub-id></element-citation></ref><ref id="b41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>FY</given-names></name><name><surname>Breitenstein</surname><given-names>S</given-names></name><name><surname>Broelsch</surname><given-names>CE</given-names></name><name><surname>Dufour</surname><given-names>JF</given-names></name><name><surname>Sherman</surname><given-names>M</given-names></name></person-group><article-title>Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma?</article-title><source>Liver Transpl</source><year>2011</year><volume>17</volume><issue>Suppl 2</issue><fpage>S109</fpage><lpage>116</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1002/lt.22335">10.1002/lt.22335</ext-link></comment><pub-id pub-id-type="pmid">21584927</pub-id></element-citation></ref><ref id="b42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pomfret</surname><given-names>EA</given-names></name><name><surname>Washburn</surname><given-names>K</given-names></name><name><surname>Wald</surname><given-names>C</given-names></name><name><surname>Nalesnik</surname><given-names>MA</given-names></name><name><surname>Douglas</surname><given-names>D</given-names></name><name><surname>Russo</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States</article-title><source>Liver Transpl</source><year>2010</year><volume>16</volume><fpage>262</fpage><lpage>278</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1002/lt.21999">10.1002/lt.21999</ext-link></comment><pub-id pub-id-type="pmid">20209641</pub-id></element-citation></ref><ref id="b43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Battiston</surname><given-names>C</given-names></name><name><surname>Perrone</surname><given-names>S</given-names></name><name><surname>Pulvirenti</surname><given-names>A</given-names></name><name><surname>Regalia</surname><given-names>E</given-names></name><name><surname>Romito</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study</article-title><source>Ann Surg</source><year>2004</year><volume>240</volume><fpage>900</fpage><lpage>909</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1097/01.sla.0000143301.56154.95">10.1097/01.sla.0000143301.56154.95</ext-link></comment><pub-id pub-id-type="pmid">15492574</pub-id></element-citation></ref><ref id="b44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>DS</given-names></name><name><surname>Yu</surname><given-names>NC</given-names></name><name><surname>Raman</surname><given-names>SS</given-names></name><name><surname>Lassman</surname><given-names>C</given-names></name><name><surname>Tong</surname><given-names>MJ</given-names></name><name><surname>Britten</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation</article-title><source>Hepatology</source><year>2005</year><volume>41</volume><fpage>1130</fpage><lpage>1137</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1002/hep.20688.">10.1002/hep.20688.</ext-link></comment><pub-id pub-id-type="pmid">15841454</pub-id></element-citation></ref><ref id="b45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majno</surname><given-names>PE</given-names></name><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Bismuth</surname><given-names>H</given-names></name><name><surname>Castaing</surname><given-names>D</given-names></name><name><surname>Ariche</surname><given-names>A</given-names></name><name><surname>Krissat</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis</article-title><source>Ann Surg</source><year>1997</year><volume>226</volume><fpage>688</fpage><lpage>701</lpage><comment>discussion 701–703, <ext-link ext-link-type="doi" xlink:href="10.1097/00000658-199712000-00006">10.1097/00000658-199712000-00006</ext-link></comment><pub-id pub-id-type="pmid">9409568</pub-id></element-citation></ref><ref id="b46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decaens</surname><given-names>T</given-names></name><name><surname>Roudot-Thoraval</surname><given-names>F</given-names></name><name><surname>Bresson-Hadni</surname><given-names>S</given-names></name><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Gugenheim</surname><given-names>J</given-names></name><name><surname>Durand</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma</article-title><source>Liver Transpl</source><year>2005</year><volume>11</volume><fpage>767</fpage><lpage>775</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1002/lt.20418">10.1002/lt.20418</ext-link></comment><pub-id pub-id-type="pmid">15973710</pub-id></element-citation></ref><ref id="b47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porrett</surname><given-names>PM</given-names></name><name><surname>Peterman</surname><given-names>H</given-names></name><name><surname>Rosen</surname><given-names>M</given-names></name><name><surname>Sonnad</surname><given-names>S</given-names></name><name><surname>Soulen</surname><given-names>M</given-names></name><name><surname>Markmann</surname><given-names>JF</given-names></name><etal></etal></person-group><article-title>Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era</article-title><source>Liver Transpl</source><year>2006</year><volume>12</volume><fpage>665</fpage><lpage>673</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1002/lt.20636">10.1002/lt.20636</ext-link></comment><pub-id pub-id-type="pmid">16482577</pub-id></element-citation></ref><ref id="b48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Mas</surname><given-names>X</given-names></name><name><surname>Aponte</surname><given-names>JJ</given-names></name><name><surname>Fuster</surname><given-names>J</given-names></name><name><surname>Navasa</surname><given-names>M</given-names></name><name><surname>Christensen</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation</article-title><source>Gut</source><year>2002</year><volume>50</volume><fpage>123</fpage><lpage>128</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1136/gut.50.1.123">10.1136/gut.50.1.123</ext-link></comment><pub-id pub-id-type="pmid">11772979</pub-id></element-citation></ref><ref id="b49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Majno</surname><given-names>P</given-names></name></person-group><article-title>Principles for the best multidisciplinary meetings</article-title><source>Lancet Oncol</source><year>2011</year><volume>12</volume><fpage>323</fpage><lpage>325</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1016/S1470-2045(11)70010-9">10.1016/S1470-2045(11)70010-9</ext-link></comment><pub-id pub-id-type="pmid">21330208</pub-id></element-citation></ref><ref id="b50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>FY</given-names></name><name><surname>Kerlan</surname><given-names>RK</given-names></name><name><surname>Hirose</surname><given-names>R</given-names></name><name><surname>Davern</surname><given-names>TJ</given-names></name><name><surname>Bass</surname><given-names>NM</given-names></name><name><surname>Feng</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis</article-title><source>Hepatology</source><year>2008</year><volume>48</volume><fpage>819</fpage><lpage>827</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1002/hep.22412">10.1002/hep.22412</ext-link></comment><pub-id pub-id-type="pmid">18688876</pub-id></element-citation></ref><ref id="b51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravaioli</surname><given-names>M</given-names></name><name><surname>Grazi</surname><given-names>GL</given-names></name><name><surname>Piscaglia</surname><given-names>F</given-names></name><name><surname>Trevisani</surname><given-names>F</given-names></name><name><surname>Cescon</surname><given-names>M</given-names></name><name><surname>Ercolani</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria</article-title><source>Am J Transplant</source><year>2008</year><volume>8</volume><fpage>2547</fpage><lpage>2557</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1111/j.1600-6143.2008.02409.x.">10.1111/j.1600-6143.2008.02409.x.</ext-link></comment><pub-id pub-id-type="pmid">19032223</pub-id></element-citation></ref><ref id="b52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Carlis</surname><given-names>L</given-names></name><name><surname>Di Sandro</surname><given-names>S</given-names></name><name><surname>Giacomoni</surname><given-names>A</given-names></name><name><surname>Slim</surname><given-names>A</given-names></name><name><surname>Lauterio</surname><given-names>A</given-names></name><name><surname>Mangoni</surname><given-names>I</given-names></name><etal></etal></person-group><article-title>Beyond the Milan criteria: what risks for patients with hepatocellular carcinoma progression before liver transplantation?</article-title><source>J Clin Gastroenterol</source><year>2012</year><volume>46</volume><fpage>78</fpage><lpage>86</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1097/MCG.0b013e31822b36f6.">10.1097/MCG.0b013e31822b36f6.</ext-link></comment><pub-id pub-id-type="pmid">21897282</pub-id></element-citation></ref><ref id="b53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mela</surname><given-names>M</given-names></name><name><surname>Mancuso</surname><given-names>A</given-names></name><name><surname>Burroughs</surname><given-names>AK</given-names></name></person-group><article-title>Review article: hepatocellular carcinoma: indications for liver transplantation</article-title><source>Aliment Pharmacol Ther</source><year>2003</year><volume>17</volume><issue>Suppl 2</issue><fpage>130</fpage><lpage>137</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1046/j.1365-2036.17.s2.16.x.">10.1046/j.1365-2036.17.s2.16.x.</ext-link></comment><pub-id pub-id-type="pmid">12786624</pub-id></element-citation></ref><ref id="b54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duvoux</surname><given-names>C</given-names></name><name><surname>Roudot-Thoraval</surname><given-names>F</given-names></name><name><surname>Decaens</surname><given-names>T</given-names></name><name><surname>Pessione</surname><given-names>F</given-names></name><name><surname>Badran</surname><given-names>H</given-names></name><name><surname>Piardi</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria</article-title><source>Gastroenterology</source><year>2012</year><volume>143</volume><fpage>986</fpage><lpage>994</lpage><comment>e983; quiz e914–985, <ext-link ext-link-type="doi" xlink:href="10.1053/j.gastro.2012.05.052">10.1053/j.gastro.2012.05.052</ext-link></comment><pub-id pub-id-type="pmid">22750200</pub-id></element-citation></ref><ref id="b55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trotter</surname><given-names>JF</given-names></name><name><surname>Wachs</surname><given-names>M</given-names></name><name><surname>Everson</surname><given-names>GT</given-names></name><name><surname>Kam</surname><given-names>I</given-names></name></person-group><article-title>Adult-to-adult transplantation of the right hepatic lobe from a living donor</article-title><source>N Engl J Med</source><year>2002</year><volume>346</volume><fpage>1074</fpage><lpage>1082</lpage><pub-id pub-id-type="pmid">11932476</pub-id></element-citation></ref><ref id="b56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clavien</surname><given-names>PA</given-names></name><name><surname>Petrowsky</surname><given-names>H</given-names></name><name><surname>DeOliveira</surname><given-names>ML</given-names></name><name><surname>Graf</surname><given-names>R</given-names></name></person-group><article-title>Strategies for safer liver surgery and partial liver transplantation</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><fpage>1545</fpage><lpage>1559</lpage><pub-id pub-id-type="pmid">17429086</pub-id></element-citation></ref><ref id="b57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruix</surname><given-names>J</given-names></name><name><surname>Llovet</surname><given-names>JM</given-names></name></person-group><article-title>Prognostic prediction and treatment strategy in hepatocellular carcinoma</article-title><source>Hepatology</source><year>2002</year><volume>35</volume><fpage>519</fpage><lpage>524</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1053/jhep.2002.32089">10.1053/jhep.2002.32089</ext-link></comment><pub-id pub-id-type="pmid">11870363</pub-id></element-citation></ref><ref id="b58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegler</surname><given-names>M</given-names></name><name><surname>Simmerling</surname><given-names>MC</given-names></name><name><surname>Siegler</surname><given-names>JH</given-names></name><name><surname>Cronin</surname><given-names>DC</given-names><suffix>2nd</suffix></name></person-group><article-title>Recipient deaths during donor surgery: a new ethical problem in living donor liver transplantation (LDLT)</article-title><source>Liver Transpl</source><year>2006</year><volume>12</volume><fpage>358</fpage><lpage>360</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1002/lt.20670">10.1002/lt.20670</ext-link></comment><pub-id pub-id-type="pmid">16498653</pub-id></element-citation></ref><ref id="b59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghobrial</surname><given-names>RM</given-names></name><name><surname>Freise</surname><given-names>CE</given-names></name><name><surname>Trotter</surname><given-names>JF</given-names></name><name><surname>Tong</surname><given-names>L</given-names></name><name><surname>Ojo</surname><given-names>AO</given-names></name><name><surname>Fair</surname><given-names>JH</given-names></name><etal></etal></person-group><article-title>Donor morbidity after living donation for liver transplantation</article-title><source>Gastroenterology</source><year>2008</year><volume>135</volume><fpage>468</fpage><lpage>476</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1053/j.gastro.2008.04.018">10.1053/j.gastro.2008.04.018</ext-link></comment><pub-id pub-id-type="pmid">18505689</pub-id></element-citation></ref><ref id="b60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Browns</surname><given-names>RS</given-names><suffix>Jr</suffix></name></person-group><article-title>Live donors in liver transplantation</article-title><source>Gastroenterology</source><year>2008</year><volume>134</volume><fpage>1802</fpage><lpage>1813</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1053/j.gastro.2008.02.092">10.1053/j.gastro.2008.02.092</ext-link></comment><pub-id pub-id-type="pmid">18471556</pub-id></element-citation></ref><ref id="b61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>CM</given-names></name><name><surname>Fan</surname><given-names>ST</given-names></name><name><surname>Liu</surname><given-names>CL</given-names></name><name><surname>Chan</surname><given-names>SC</given-names></name><name><surname>Ng</surname><given-names>IO</given-names></name><name><surname>Wong</surname><given-names>J</given-names></name></person-group><article-title>Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma</article-title><source>Br J Surg</source><year>2007</year><volume>94</volume><fpage>78</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">17016793</pub-id></element-citation></ref><ref id="b62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>RA</given-names></name><name><surname>Kulik</surname><given-names>LM</given-names></name><name><surname>Freise</surname><given-names>CE</given-names></name><name><surname>Lok</surname><given-names>AS</given-names></name><name><surname>Shearon</surname><given-names>TH</given-names></name><name><surname>Brown</surname><given-names>RS</given-names><suffix>Jr</suffix></name><etal></etal><collab>A2ALL Study Group</collab></person-group><article-title>Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation</article-title><source>Am J Transplant</source><year>2007</year><volume>7</volume><fpage>1601</fpage><lpage>1608</lpage><pub-id pub-id-type="pmid">17511683</pub-id></element-citation></ref><ref id="b63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarasin</surname><given-names>FP</given-names></name><name><surname>Majno</surname><given-names>PE</given-names></name><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Bruix</surname><given-names>J</given-names></name><name><surname>Mentha</surname><given-names>G</given-names></name><name><surname>Hadengue</surname><given-names>A</given-names></name></person-group><article-title>Living donor liver transplantation for early hepatocellular carcinoma: a lifeexpectancy and cost–effectiveness perspective</article-title><source>Hepatology</source><year>2001</year><volume>33</volume><fpage>1073</fpage><lpage>1079</lpage><pub-id pub-id-type="pmid">11343234</pub-id></element-citation></ref><ref id="b64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Ricci</surname><given-names>S</given-names></name><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Hilgard</surname><given-names>P</given-names></name><name><surname>Gane</surname><given-names>E</given-names></name><name><surname>Blanc</surname><given-names>JF</given-names></name><etal></etal></person-group><article-title>SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>378</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">18650514</pub-id></element-citation></ref><ref id="b65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Tsao</surname><given-names>CJ</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name><etal></etal></person-group><article-title>Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial</article-title><source>Lancet Oncol</source><year>2009</year><volume>10</volume><fpage>25</fpage><lpage>34</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1016/S1470-2045(08)70285-7">10.1016/S1470-2045(08)70285-7</ext-link></comment><pub-id pub-id-type="pmid">19095497</pub-id></element-citation></ref><ref id="b66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeiffenberger</surname><given-names>J</given-names></name><name><surname>Koschny</surname><given-names>R</given-names></name><name><surname>Hoffmann</surname><given-names>K</given-names></name><name><surname>Mehrabi</surname><given-names>A</given-names></name><name><surname>Schmitz</surname><given-names>A</given-names></name><name><surname>Radeleff</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation</article-title><source>Langenbecks Arch Surg</source><year>2013</year><volume>398</volume><fpage>1123</fpage><lpage>1128</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1007/s00423-013-1114-1">10.1007/s00423-013-1114-1</ext-link></comment><pub-id pub-id-type="pmid">24091908</pub-id></element-citation></ref><ref id="b67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waghray</surname><given-names>A</given-names></name><name><surname>Balci</surname><given-names>B</given-names></name><name><surname>El-Gazzaz</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>R</given-names></name><name><surname>Pelley</surname><given-names>R</given-names></name><name><surname>Narayanan Menon</surname><given-names>KV</given-names></name><etal></etal></person-group><article-title>Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation</article-title><source>Clin Transplant</source><year>2013</year><volume>27</volume><fpage>555</fpage><lpage>561</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1111/ctr.12150">10.1111/ctr.12150</ext-link></comment><pub-id pub-id-type="pmid">23758296</pub-id></element-citation></ref><ref id="b68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sposito</surname><given-names>C</given-names></name><name><surname>Mariani</surname><given-names>L</given-names></name><name><surname>Germini</surname><given-names>A</given-names></name><name><surname>Flores Reyes</surname><given-names>M</given-names></name><name><surname>Bongini</surname><given-names>M</given-names></name><name><surname>Grossi</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study</article-title><source>J Hepatol</source><year>2013</year><volume>59</volume><fpage>59</fpage><lpage>66</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1016/j.jhep.2013.02.026">10.1016/j.jhep.2013.02.026</ext-link></comment><pub-id pub-id-type="pmid">23500153</pub-id></element-citation></ref><ref id="b69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotiropoulos</surname><given-names>GC</given-names></name><name><surname>Nowak</surname><given-names>KW</given-names></name><name><surname>Fouzas</surname><given-names>I</given-names></name><name><surname>Vernadakis</surname><given-names>S</given-names></name><name><surname>Kykalos</surname><given-names>S</given-names></name><name><surname>Klein</surname><given-names>CG</given-names></name><etal></etal></person-group><article-title>Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation</article-title><source>Transplant Proc</source><year>2012</year><volume>44</volume><fpage>2754</fpage><lpage>2756</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1016/j.transproceed.2012.09.022">10.1016/j.transproceed.2012.09.022</ext-link></comment><pub-id pub-id-type="pmid">23146514</pub-id></element-citation></ref><ref id="b70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zavaglia</surname><given-names>C</given-names></name><name><surname>Airoldi</surname><given-names>A</given-names></name><name><surname>Mancuso</surname><given-names>A</given-names></name><name><surname>Vangeli</surname><given-names>M</given-names></name><name><surname>Viganò</surname><given-names>R</given-names></name><name><surname>Cordone</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature</article-title><source>Eur J Gastroenterol Hepatol</source><year>2013</year><volume>25</volume><fpage>180</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">23044808</pub-id></element-citation></ref><ref id="b71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vitale</surname><given-names>A</given-names></name><name><surname>Boccagni</surname><given-names>P</given-names></name><name><surname>Kertusha</surname><given-names>X</given-names></name><name><surname>Zanus</surname><given-names>G</given-names></name><name><surname>D'Amico</surname><given-names>F</given-names></name><name><surname>Lodo</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation?</article-title><source>Transplant Proc</source><year>2012</year><volume>44</volume><fpage>1989</fpage><lpage>91</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1016/j.transproceed.2012.06.046">10.1016/j.transproceed.2012.06.046</ext-link></comment><pub-id pub-id-type="pmid">22974889</pub-id></element-citation></ref><ref id="b72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staufer</surname><given-names>K</given-names></name><name><surname>Fischer</surname><given-names>L</given-names></name><name><surname>Seegers</surname><given-names>B</given-names></name><name><surname>Vettorazzi</surname><given-names>E</given-names></name><name><surname>Nashan</surname><given-names>B</given-names></name><name><surname>Sterneck</surname><given-names>M</given-names></name></person-group><article-title>High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation</article-title><source>Transpl Int</source><year>2012</year><volume>25</volume><fpage>1158</fpage><lpage>64</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1111/j.1432-2277.2012.01540.x">10.1111/j.1432-2277.2012.01540.x</ext-link></comment><pub-id pub-id-type="pmid">22882364</pub-id></element-citation></ref><ref id="b73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinmann</surname><given-names>A</given-names></name><name><surname>Niederle</surname><given-names>IM</given-names></name><name><surname>Koch</surname><given-names>S</given-names></name><name><surname>Hoppe-Lotichius</surname><given-names>M</given-names></name><name><surname>Heise</surname><given-names>M</given-names></name><name><surname>Düber</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation</article-title><source>Dig Liver Dis</source><year>2012</year><volume>44</volume><fpage>432</fpage><lpage>437</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1016/j.dld.2011.12.009">10.1016/j.dld.2011.12.009</ext-link></comment><pub-id pub-id-type="pmid">22265328</pub-id></element-citation></ref><ref id="b74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfiffer</surname><given-names>TE</given-names></name><name><surname>Seehofer</surname><given-names>D</given-names></name><name><surname>Nicolaou</surname><given-names>A</given-names></name><name><surname>Neuhaus</surname><given-names>R</given-names></name><name><surname>Riess</surname><given-names>H</given-names></name><name><surname>Trappe</surname><given-names>RU</given-names></name></person-group><article-title>Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era</article-title><source>Tumori</source><year>2011</year><volume>97</volume><fpage>436</fpage><lpage>441</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1700/950.10394">10.1700/950.10394</ext-link></comment><pub-id pub-id-type="pmid">21989430</pub-id></element-citation></ref><ref id="b75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Martin</surname><given-names>C</given-names></name><name><surname>Bustamante</surname><given-names>J</given-names></name><name><surname>Castroagudin</surname><given-names>JF</given-names></name><name><surname>Salcedo</surname><given-names>M</given-names></name><name><surname>Garralda</surname><given-names>E</given-names></name><name><surname>Testillano</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation</article-title><source>Liver Transpl</source><year>2012</year><volume>18</volume><fpage>45</fpage><lpage>52</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1002/lt.22434">10.1002/lt.22434</ext-link></comment><pub-id pub-id-type="pmid">21932373</pub-id></element-citation></ref><ref id="b76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>WF</given-names></name><name><surname>Qiu</surname><given-names>ZQ</given-names></name><name><surname>YU</surname><given-names>Y</given-names></name><name><surname>Ran</surname><given-names>RZ</given-names></name><name><surname>Yi</surname><given-names>B</given-names></name><name><surname>Lau</surname><given-names>WY</given-names></name><etal></etal></person-group><article-title>Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation</article-title><source>Acta Pharmacol Sin</source><year>2010</year><volume>31</volume><fpage>1643</fpage><lpage>1648</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1038/aps.2010.124">10.1038/aps.2010.124</ext-link></comment><pub-id pub-id-type="pmid">21102481</pub-id></element-citation></ref><ref id="b77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>R</given-names></name><name><surname>El-Gazzaz</surname><given-names>G</given-names></name><name><surname>Tan</surname><given-names>A</given-names></name><name><surname>Elson</surname><given-names>P</given-names></name><name><surname>Byrne</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>YD</given-names></name><etal></etal></person-group><article-title>Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation</article-title><source>Oncology</source><year>2010</year><volume>79</volume><fpage>62</fpage><lpage>66</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1159/000319548">10.1159/000319548</ext-link></comment><pub-id pub-id-type="pmid">21071991</pub-id></element-citation></ref><ref id="b78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>DH</given-names></name><name><surname>Ryoo</surname><given-names>BY</given-names></name><name><surname>Ryu</surname><given-names>MH</given-names></name><name><surname>Lee</surname><given-names>SG</given-names></name><name><surname>Hwang</surname><given-names>S</given-names></name><name><surname>Suh</surname><given-names>DJ</given-names></name><etal></etal></person-group><article-title>Jpn Sorafenib for recurrent hepatocellular carcinoma after liver transplantation</article-title><source>J Clin Oncol</source><year>2010</year><volume>40</volume><fpage>768</fpage><lpage>773</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1093/jjco/hyq055">10.1093/jjco/hyq055</ext-link></comment></element-citation></ref><ref id="b79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valdivieso</surname><given-names>A</given-names></name><name><surname>Bustamante</surname><given-names>J</given-names></name><name><surname>Gastaca</surname><given-names>M</given-names></name><name><surname>Uriarte</surname><given-names>JG</given-names></name><name><surname>Ventoso</surname><given-names>A</given-names></name><name><surname>Ruiz</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Management of hepatocellular carcinoma recurrence after liver transplantation</article-title><source>Transplant Proc</source><year>2010</year><volume>42</volume><fpage>660</fpage><lpage>662</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1016/j.transproceed.2010.02.014">10.1016/j.transproceed.2010.02.014</ext-link></comment><pub-id pub-id-type="pmid">20304217</pub-id></element-citation></ref><ref id="b80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feun</surname><given-names>LG</given-names></name><name><surname>Levi</surname><given-names>D</given-names></name><name><surname>Moon</surname><given-names>J</given-names></name><name><surname>Nishida</surname><given-names>S</given-names></name><name><surname>Island</surname><given-names>E</given-names></name><name><surname>Selvaggi</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Sorafenib in hepatocellular carcinoma (HCC) patients after liver transplantation</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>suppl 20</issue><fpage>e15579</fpage></element-citation></ref><ref id="b81"><label>81</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Derancy</surname><given-names>S</given-names></name><name><surname>Romano</surname><given-names>O</given-names></name><name><surname>Lorho</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Tolerability and efficacy ofsorafennib in recurrent hepatocellularcarcinoma after livertransplantation: a case-control study</article-title><source>Abstract book EASL</source><year>2010</year></element-citation></ref><ref id="b82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toso</surname><given-names>C</given-names></name><name><surname>Mentha</surname><given-names>G</given-names></name><name><surname>Majno</surname><given-names>P</given-names></name></person-group><article-title>Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence</article-title><source>J Hepatol</source><year>2013</year><volume>59</volume><fpage>3</fpage><lpage>5</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1016/j.jhep.2013.03.029">10.1016/j.jhep.2013.03.029</ext-link></comment><pub-id pub-id-type="pmid">23567081</pub-id></element-citation></ref><ref id="b83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancuso</surname><given-names>A</given-names></name><name><surname>Mazzarelli</surname><given-names>C</given-names></name><name><surname>Perricone</surname><given-names>G</given-names></name><name><surname>Zavaglia</surname><given-names>C</given-names></name></person-group><article-title>Sorafenib efficacy for treatment of HCC recurrence after Liver Transplantation is an open issue</article-title><source>J Hepatol</source><year>2014</year><volume>60</volume><fpage>681</fpage><comment><ext-link ext-link-type="doi" xlink:href="10.1016/j.jhep.2013.10.030">10.1016/j.jhep.2013.10.030</ext-link></comment><pub-id pub-id-type="pmid">24216445</pub-id></element-citation></ref><ref id="b84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sposito</surname><given-names>C</given-names></name><name><surname>Mazzaferro</surname><given-names>V</given-names></name></person-group><article-title>Reply to “Sorafenib efficacy for treatment of HCC recurrence after Liver Transplantation is an open issue”</article-title><source>J Hepatol</source><year>2014</year><volume>60</volume><fpage>682</fpage><lpage>683</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1016/j.jhep.2013.10.032">10.1016/j.jhep.2013.10.032</ext-link></comment><pub-id pub-id-type="pmid">24216444</pub-id></element-citation></ref><ref id="b85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancuso</surname><given-names>A</given-names></name><name><surname>Airoldi</surname><given-names>A</given-names></name><name><surname>Vigano</surname><given-names>R</given-names></name><name><surname>Pinzello</surname><given-names>G</given-names></name></person-group><article-title>Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation</article-title><source>Dig Liver Dis</source><year>2011</year><volume>43</volume><fpage>754</fpage><comment><ext-link ext-link-type="doi" xlink:href="10.1016/j.dld.2011.04.022">10.1016/j.dld.2011.04.022</ext-link></comment><pub-id pub-id-type="pmid">21641889</pub-id></element-citation></ref><ref id="b86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancuso</surname></name><name><surname>Zavaglia</surname><given-names>C</given-names></name><name><surname>Bai</surname><given-names>F</given-names></name><name><surname>Puoti</surname><given-names>M</given-names></name><name><surname>Belli</surname><given-names>L</given-names></name></person-group><article-title>Sorafenib hepatotoxicity seems to be enhanced by HAARTS interaction during treatment of advanced hepatocelluler carcinoma in HIV-infected patients</article-title><source>Aliment Pharmacol Ther</source><year>2013</year><volume>38</volume><fpage>1414</fpage><lpage>1416</lpage><comment><ext-link ext-link-type="doi" xlink:href="10.1111/apt.12536">10.1111/apt.12536</ext-link></comment><pub-id pub-id-type="pmid">24206381</pub-id></element-citation></ref></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term>AAIR</term><def><p>age-adjusted incidence rate</p></def></def-item><def-item><term>EASL-EORTC</term><def><p>European Association for the Study of the Liver – European Organisation for Research and Treatment of Cancer</p></def></def-item><def-item><term>ELTR</term><def><p>European Liver Transplant Registry</p></def></def-item><def-item><term>HAART</term><def><p>highly active anti-retroviral therapy</p></def></def-item><def-item><term>HBV</term><def><p>hepatitis B virus</p></def></def-item><def-item><term>HCC</term><def><p>hepatocellular carcinoma</p></def></def-item><def-item><term>HCV</term><def><p>hepatitis C virus</p></def></def-item><def-item><term>HIV</term><def><p>human immunodeficiency virus</p></def></def-item><def-item><term>ITT</term><def><p>intention-to-treat</p></def></def-item><def-item><term>LDLT</term><def><p>living donor liver transplantation</p></def></def-item><def-item><term>LT</term><def><p>liver transplantation</p></def></def-item><def-item><term>MC</term><def><p>Milan criteria</p></def></def-item><def-item><term>NASH</term><def><p>non-alcoholic steatohepatitis</p></def></def-item><def-item><term>OPTN</term><def><p>organ procurement and transplantation network</p></def></def-item><def-item><term>RFA</term><def><p>radio-frequency ablation</p></def></def-item><def-item><term>RFTA</term><def><p>radio-frequency thermal ablation</p></def></def-item><def-item><term>TACE</term><def><p>trans-arterial chemoembolization</p></def></def-item><def-item><term>UNOS</term><def><p>United Network for Organ Sharing</p></def></def-item><def-item><term>UCSF</term><def><p>University of San Francisco</p></def></def-item></def-list></glossary></back></article>